Health ConditionsThe term liver detoxification carries two distinct meanings that are frequently conflated in public discourse. In rigorous biological science, it refers to the liver's continuous, endogenous process of transforming xenobiotics — foreign or potentially harmful chemical substances — and endogenously produced metabolic waste into forms that can be excreted from the body. Detoxification, or biotransformation, is an ongoing, natural process of the body involving primarily the liver, kidneys, and skin to remove waste products and endogenously or exogenously acquired toxins. In the popular wellness and natural-health context, the term is often applied to commercial dietary regimens, herbal supplements, juice cleanses, and fasting protocols that claim to "cleanse," "support," or enhance this innate function. These two meanings — the physiological process and the consumer concept — must be kept clearly distinct for accurate evaluation of evidence.
The liver's role as the body's primary chemical processing organ is well established. The liver plays an important role in protecting the organism from potentially toxic chemical insults through its capacity to convert lipophiles into more water-soluble metabolites which can be efficiently eliminated from the body via the urine. The liver is the main organ for metabolic and detoxification reactions in the body, and therefore its diseases can be associated with both metabolic disorders, such as insulin resistance, obesity, diabetes, or dyslipidemia, and exogenous insults such as drugs, xenobiotics, or alcohol.
The commercial "liver detox" concept is assessed skeptically by major health authorities. A 2015 review concluded that there was no compelling research to support the use of "detox" diets for weight management or eliminating toxins from the body. Despite popular claims, there is little scientific evidence that commercial detox diets or cleanses enhance the body's natural processes. A 2023 analysis of the top 10 selling liver detox products found no definitive evidence that they were effective in improving liver function or health.
The liver functions to transform xenobiotics mainly by converting them from a lipophilic form to a hydrophilic form through two reactions — phase I and phase II — which mainly take place in the smooth endoplasmic reticulum of hepatocytes. The "Phase I" cytochrome P450 superfamily of enzymes (CYP450) is generally the first defense employed by the body to biotransform xenobiotics, steroid hormones, and pharmaceuticals. These microsomal membrane-bound, heme-thiolate proteins, located mainly in the liver, but also in enterocytes, kidneys, lung, and even the brain, are responsible for the oxidation, peroxidation, and reduction of several endogenous and exogenous substrates.
Beyond the liver, the kidneys serve as the primary route for excreting water-soluble conjugates produced by hepatic biotransformation. Dietary fiber can greatly alter the gut milieu by affecting the gut microbiome, which in turn influences the gut barrier, gastrointestinal immune and endocrine responses, and nitrogen cycling and microbial metabolism; these gut-associated changes can then alter the physiology and biochemistry of the body's other main nutrient management and detoxification organs, the liver and kidneys. The molecular mechanisms by which dietary fiber alters the physiology of the gut, liver, and kidneys is likely through gut-localized events coupled with specific factors that signal to or affect the physiology of the liver and kidneys.
Phase I reactions create a more hydrophilic solute via oxidation, reduction, and hydrolysis using primarily the cytochrome P450 (CYP450) family of enzymes. The "phases" of detoxification were described as functionalization (or phase I), involving the addition of oxygen to form a reactive site on the toxic compound, and conjugation (phase II), the process of adding a water-soluble group to this now reactive site. An important nuance is that some chemicals may also be converted to more toxic metabolites by certain of these enzymes, implying that variations in the latter may be important predisposing factors for toxicity. Thus, Phase I activity does not always immediately reduce toxicity; it creates reactive intermediates that must be efficiently handled by Phase II.
In Phase II, conjugation enzymes join activated xenobiotics with large molecules to produce water-soluble substances that are finally excreted from the body in Phase III, the elimination phase, mainly via urine or stools. There are a number of enzymes which catalyse phase II detoxification, for example heme oxygenase 1, NAD(P)H dehydrogenase quinone 1, glutathione reductase, glutamate cysteine ligase, glutathione S-transferase, and UDP-glucuronosyltransferase. Glutathione S-transferase is among the most important of these, as it links the master antioxidant glutathione to reactive electrophilic intermediates produced in Phase I.
Phase III detoxification involves the transport and elimination of conjugated toxins out of hepatocytes, primarily into the bile or urine for excretion, ensuring their removal from the body. The distinction between Phase II and Phase III is significant from a nutritional standpoint because bile production and flow — influenced by dietary fat, fiber, and certain herbs — is integral to excreting fat-soluble conjugated compounds through the digestive tract.
Metabolic detoxification — or biotransformation — is a physiological function that removes toxic substances from the body. Genetic variability and dietary factors may affect the function of detox enzymes, thus impacting the body's sensitivity to toxic substances of endogenous and exogenous origin. From a genetic perspective, most of the current knowledge relies on observational studies in humans or experimental models in vivo and in vitro, with very limited proof of causality and clinical value. Pharmacogenetic defects of xenobiotic biotransformation enzymes, a subclass of inborn errors of metabolism which are manifested only upon drug challenge, introduce marked variation into human populations for the pharmacokinetics and pharmacodynamics of therapeutic and toxic agents, and may have important clinical consequences for drug efficacy and toxicity.
Non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated liver disease (MASLD), is a spectrum of liver disease characterized by steatosis in hepatocytes with minimal or no alcohol use. Because of its rising incidence along with increasing rates of obesity, metabolic syndromes, and type 2 diabetes mellitus, NAFLD is expected to overtake all other causes of cirrhosis over the next decade, necessitating liver transplantation. Pathologically, NAFLD is linked to lipid toxicity, oxidative stress, lipid deposits, and endoplasmic reticulum stress.
A systematic review revealed that clinical conditions such as obesity, weight change, psoriasis, polycystic ovary syndrome, diabetes, thyroid disorders, and elevated serum uric acid levels increase the risk of developing nonalcoholic fatty liver. In addition, lifestyle factors such as sedentary behavior, active or passive smoking, poor sleep quality, and consumption of carbonated beverages are associated with this condition.
Alcohol is a well-characterized direct hepatotoxin. While early epidemiological studies indicated that moderate alcohol consumption does not contribute to the development of NAFLD, increasing evidence suggests that alcohol consumption can be a risk factor for NAFLD. Major liver organizations including the Latin American Association for the Study of the Liver advise patients with NAFLD to avoid alcohol, while European clinical guidelines suggest abstinence or strict adherence to alcohol intake below the risk threshold (30 g in men and 20 g in women) in individuals with NAFLD and the absence of cirrhosis.
It is understood that mitochondrial-generated oxidative stress and abnormalities in Phase I/II metabolism, leading to glutathione (GSH) suppression, drive the onset of DILI. N-acetylcysteine (NAC) has attracted considerable interest as a therapeutic agent against DILI because of its strong antioxidant properties, especially in relation to enhancing endogenous GSH content to counteract oxidative stress. Both over-the-counter supplements marketed for liver support and conventional pharmaceuticals are known causes of DILI.
High fructose consumption is a well-known risk factor for NAFLD/NASH, especially in children and adolescents. In a study of young nonobese individuals without metabolic risk factors, the single independent factor for the detection of NAFLD was higher juice and soft drink intake, contributing up to a four-fold increase in risk of NAFLD compared with individuals consuming less sugar-sweetened beverages.
Oxidative stress is a key pathological feature implicated in both acute and chronic liver diseases, including drug-induced liver injury. Diets high in refined carbohydrates, trans fats, and processed meats contribute to oxidative stress, inflammation, and steatosis, thereby taxing the liver. This provides a mechanistic rationale for studying antioxidant-rich foods and phytonutrients in the context of hepatic health.
NAFLD and related metabolic conditions share risk factors such as unhealthy diet, low physical activity, and especially obesity. An umbrella review of more than 380,000 participants identified physical activity as one of only two factors with suggestive evidence for a protective effect against NAFLD.
Cirrhosis usually represents end-stage liver disease, and as such, liver function is greatly compromised. The diminished ability to produce protein and detoxify substances results in symptoms of portal hypertension, hyperestrinism, and hypoalbuminemia. Decreased clotting factor synthesis results in coagulopathy. These end-stage consequences underscore the importance of understanding earlier-stage contributing factors discussed in the nutritional literature.
Traditional use: The scientific name for milk thistle is Silybum marianum. It is a member of the aster or daisy family and has been used by ancient physicians and herbalists to treat a range of liver and gallbladder diseases and to protect the liver against a variety of poisons. Its use extends from ancient Mediterranean practice through European folk medicine and the German Commission E.
Active constituents and proposed mechanisms: Silymarin, extracted from milk thistle (Silybum marianum), is esteemed for its antioxidative, anti-inflammatory, and antifibrotic properties, notably within liver-related contexts. Evidence exists that milk thistle may be hepatoprotective through a number of mechanisms: antioxidant activity, toxin blockade at the membrane level, enhanced protein synthesis, antifibrotic activity, and possible anti-inflammatory or immunomodulating effects.
Scientific evidence: Milk thistle is promoted as a dietary supplement for liver disorders, diabetes, and other conditions; however, there isn't enough high-quality evidence to allow definite conclusions to be reached about the effects of milk thistle on health conditions in people. Results from clinical trials of milk thistle for liver diseases, such as alcohol-related liver disease, hepatitis B and C, non-alcoholic fatty liver disease, and liver problems caused by cancer chemotherapy, low oxygen levels, or toxins, have been conflicting or too limited to draw firm conclusions.
Key clinical trial data include a large, multicenter, double-blind, placebo-controlled trial. The botanical product silymarin, an extract of milk thistle, is commonly used by patients to treat chronic liver disease, despite scant and conflicting evidence of its efficacy. This multicenter, double-blind, placebo-controlled trial was conducted at 4 medical centers in the United States and included 154 persons with chronic HCV infection and serum alanine aminotransferase (ALT) levels of 65 U/L or greater who were previously unsuccessfully treated with interferon-based therapy. A 2017 systematic review and meta-analysis of 23 trials evaluated the effect of silymarin on the serum levels of ALT, AST, and gamma glutamyl transpeptidase in patients with liver diseases. The authors concluded that silymarin minimally reduced the serum levels of ALT and AST; however, the results were without clinical relevance. They also noted the need to conduct studies with more appropriate methodological designs.
One area of more consistently positive findings is drug-induced liver injury. A randomized clinical trial in children with acute lymphoblastic leukemia found that silymarin decreased the side effects of chemotherapy on the liver without harming the cancer treatment.
Evidence strength: Overall, the evidence is mixed and insufficiently robust to support definitive clinical recommendations for silymarin in liver disease according to NCCIH. A systematic review following PRISMA 2020 guidelines found 29 RCTs meeting inclusion criteria, encompassing 3,846 participants with diverse underlying conditions, but heterogeneity across studies limits pooled conclusions. Available evidence from clinical trials in people with liver diseases suggests that milk thistle is generally well-tolerated.
Traditional use: Curcumin is the main constituent of turmeric, the rhizome of Curcuma longa, which is a widely used spice, coloring agent, and source of curcumin. Turmeric has been used for thousands of years in Ayurvedic and traditional Chinese medicine systems as a digestive, anti-inflammatory, and hepatoprotective agent, typically as a culinary spice and prepared in decoctions or pastes.
Proposed mechanisms: Curcumin acts as an anti-inflammatory, antioxidant, anti-diabetic, anti-hyperlipidemia, immune-modulatory, reno-protective, anti-cancer, hepato-protective, hypoglycemic, antimicrobial, and anti-fibrotic agent.
Scientific evidence: A 2023 GRADE-assessed systematic review and dose-response meta-analysis of RCTs found that turmeric/curcumin supplementation might be effective in improving AST and ALT levels; however, further clinical trials are needed to examine its effect on GGT. The quality of the evidence across studies was low for AST and ALT and very low for GGT. Therefore, more studies with high quality are needed to assess this intervention on hepatic health.
A separate meta-analysis focusing on NAFLD found curcumin supplementation significantly reduced ALT and AST levels compared to the placebo group in seven trials (p = 0.049, p = 0.032, respectively). It also reduced serum LDL concentration but not TG or HDL levels. However, a larger meta-analysis incorporating 14 clinical trials reported that curcumin had no statistically significant effect on ALT, AST, alkaline phosphatase, glycated hemoglobin, or BMI.
A major limitation is bioavailability. Curcumin has low bioavailability; however, several clinical trials as well as preclinical studies confirmed the protective and therapeutic effects of curcumin in different oxidative-associated diseases including liver disorders. Different evidence has suggested that the therapeutic activities of this natural molecule, despite its undesirable pharmacokinetic properties, are mainly due to the main metabolites of curcumin.
Evidence strength: Preliminary to moderate; results are inconsistent across meta-analyses due to heterogeneous populations, formulations, dosages, and bioavailability issues. Evidence is rated low to very low quality by GRADE assessment. The NIH LiverTox database notes that among 300 cases of drug-induced liver disease in the US collected between 2004 and 2008, 9% of cases were attributed to herbal medications, but none were linked to turmeric or curcumin use, suggesting an acceptable safety profile at culinary and standard supplemental doses.
Background: The primary role of NAC as an antioxidant stems from its ability to increase the intracellular concentration of glutathione (GSH), which is the most crucial biothiol responsible for cellular redox imbalance. Glutathione is the main endogenous substrate for Phase II conjugation reactions and is rapidly depleted under conditions of high oxidative or toxic stress.
Scientific evidence — acetaminophen toxicity: N-acetylcysteine (NAC) is the mainstay of therapy for acetaminophen toxicity. NAC has FDA approval for treating potentially hepatotoxic doses of acetaminophen and is almost 100% effective if given within 8 hours post-ingestion. Cysteine is a conditionally essential amino acid; endogenous synthesis is insufficient during periods of oxidative stress, thus explaining why glutathione levels drop substantially during inflammation and other endogenous and exogenous insults, and why NAC can have such a dramatic restorative effect when administered relatively early in the acute liver injury cascade.
Scientific evidence — broader DILI: NAC has attracted considerable interest as a therapeutic agent against DILI because of its strong antioxidant properties, especially in relation to enhancing endogenous GSH content to counteract oxidative stress. In addition to updating information on the pathophysiological mechanisms implicated in oxidative-induced hepatic injury, clinical evidence supports protective effects of NAC against DILI, including the reduction of patient mortality. A systematic search through major search engines retrieved 12 relevant RCTs reporting on the impact of NAC infusion on liver function in patients with DILI.
As an anti-inflammatory compound, NAC can reduce levels of TNF-α and interleukins (IL-6 and IL-1β) by suppressing the activity of NF-κB. Despite NAC's relevant therapeutic potential, in several experimental studies, its effectiveness in clinical trials addressing different pathological conditions is still limited.
Evidence strength: Strong for acetaminophen overdose (standard medical practice); moderate for drug-induced liver injury in clinical settings; preliminary for general nutritional "liver support" in otherwise healthy individuals.
Traditional use: Worldwide, the root of the dandelion has been used to treat a variety of liver and gallbladder problems. Other historical uses of the root and leaves include treating breast diseases, water retention, digestive problems, joint pain, fever, and skin diseases. Dandelion leaves contain substantial levels of vitamins A, C, D, and B complex as well as iron, magnesium, zinc, potassium, manganese, copper, choline, calcium, boron, and silicon.
Scientific evidence: Preclinical (animal and cell) studies suggest hepatoprotective activity. Dandelion root (Taraxacum officinale) has been shown in preclinical studies to increase hepatic antioxidant activities, including catalase, GST, GPx, and GSH reductase. It also exerts hepatoprotective effects by having the ability to reduce fibrinous deposits and to support a healthy hepatic inflammatory response. Dandelion root and artichoke leaf stimulate bile flow, which aids in the emulsification and excretion of fat-soluble waste products, though human clinical data supporting their benefits remains limited.
Evidence strength: Very preliminary; the evidence base is largely preclinical (in vitro and animal). Robust human RCTs are lacking as of the time of current reviews.
Traditional use: Artichoke leaf has been used in European herbal medicine, notably in the Mediterranean region, for centuries as a digestive tonic and to promote bile production and liver function. The German Commission E has assessed artichoke leaf for dyspeptic complaints.
Scientific evidence: Artichoke extract (Cynara scolymus) not only upregulates enzymatic reactions in Phase I and Phase II detoxification but also exhibits choleretic activity and has been shown to increase bile flow and the formation of bile compounds, which is crucial for the excretion of conjugated toxic substances. An animal study found that artichoke preparation, owing to its high antioxidative potential, exhibits protective and regenerative effects on the liver, as supported by the observation of higher GSH levels in plasma of rats treated with artichoke extract before CClâ‚„ exposure, and lower ALT, AST, and SOD activity in the group treated with artichoke extract after CClâ‚„ exposure. An umbrella review found that positive effects were observed for artichoke, among other natural products, on certain liver enzymes.
Evidence strength: Preliminary; most evidence is from animal models and small clinical studies. Human RCTs are limited in size and design quality.
Traditional use: Cruciferous vegetables (broccoli, cabbage, Brussels sprouts, kale, cauliflower, watercress) have long been dietary staples across Asian, European, and Mediterranean food traditions, with historical associations with digestive health and cancer prevention in multiple cultures.
Scientific evidence: Glucosinolates are hydrolysed by the myrosinase enzyme found in plant tissues and converted into biologically active compounds such as indoles (indole-3-carbinol) and isothiocyanates (sulforaphane), which have been shown to have anticarcinogenic properties in vitro and animal studies. Indole-3-carbinol (I3C) is a resulting compound that comes from eating vegetables such as Brussels sprouts, cabbage, cauliflower, broccoli, and kale. It is known to stimulate detoxifying enzymes in the gut and liver. The main mechanism of carcinogenesis inhibition described for isothiocyanates (ITCs) appears to occur through two levels of the detoxification pathway: selective P450 enzyme inhibition or activation, and an induction of Phase II enzymes, preventing the activation of procarcinogens and increasing their excretion.
A PMC-published scientific review noted clinical evidence of effects from cruciferous vegetables (in combination, and specifically watercress, garden cress, and broccoli), allium vegetables, apiaceous vegetables, grapefruit, resveratrol, fish oil, quercetin, daidzein, and lycopene on detoxification enzyme activity. However, two components of cruciferous vegetables, sulforaphanes and indole-3-carbinol, inhibited and increased CYP activity respectively, highlighting the potential for human studies using whole foods to clarify the outcome of consumption. Variations in the sequence of genes coding for Phase II detoxification enzymes, glutathione S-transferases (GSTs), may influence the potential health benefits of consuming cruciferous vegetables.
Evidence strength: Moderate for enzyme modulation effects in preclinical and some human metabolic studies; insufficient for specific therapeutic claims in liver disease without further RCT evidence. The whole-food form appears more consistently beneficial than isolated supplements.
Traditional Chinese Medicine (TCM) views the liver in terms of vital energy (qi) and the storage of blood (xue). Together with the scheme of Yin Yang, TCM practitioners may diagnose liver disorders and offer treatments like acupuncture or herbs. Numerous Chinese herbal formulas are directed at "liver qi stagnation" and liver-blood deficiency. Because there have been very few good quality studies, there is no strong proof that Chinese herbal products work for liver health, according to current systematic assessments. Since ancient times, herbals have been used for preventive and therapeutic purposes because of their anti-apoptotic, anti-inflammatory, and antioxidant effects, but the indications and posology of specific plants need to be clarified through multicenter, randomized clinical trials.
Glutathione (GSH) is the liver's primary endogenous antioxidant and a critical cofactor in Phase II conjugation. Its synthesis depends on the availability of the precursor amino acid cysteine (supplied by NAC or dietary methionine/cysteine), glycine, and glutamate. In a well-nourished individual without glutathione synthetase (GSS) mutations, glutathione exists in concentrations adequate for detoxification at low levels. However, stores can be quickly depleted with significant toxin exposure or other physiologic insult. Methionine and taurine are sulfur-containing amino acids that feed into GSH synthesis and bile acid conjugation pathways respectively, and both appear in the research literature and traditional preparations targeting liver function.
Several B vitamins serve as cofactors for Phase II methylation reactions in hepatic detoxification. Folate, B6 (pyridoxine), and B12 (cobalamin) are required for one-carbon metabolism and homocysteine remethylation, pathways with direct consequences for hepatic methyl-donor availability. Riboflavin (B2) is required for the activity of flavin-containing monooxygenases (FMOs), a secondary family of Phase I oxidation enzymes. These nutrient dependencies are well-characterized in biochemistry, but robust clinical trials specifically linking B-vitamin supplementation to improved hepatic detoxification outcomes in healthy humans are limited.
Choline is an essential nutrient required for hepatic very-low-density lipoprotein (VLDL) synthesis and export of fat from the liver. Choline deficiency is a well-recognized experimental model for inducing hepatic steatosis. Dandelion leaves, among other plant foods, contain meaningful amounts of choline, and choline appears as an ingredient in numerous commercially formulated liver-support supplements. The NIH Office of Dietary Supplements recognizes choline's role in fat transport and liver metabolism, though evidence for supplemental choline improving liver function beyond correcting deficiency is not consistently demonstrated in well-nourished populations.
Positive effects were observed for vitamin E, among other natural products, on certain liver enzymes in a 2023 umbrella review of 40 meta-analyses. Vitamin E (alpha-tocopherol) has been investigated specifically in NASH/NAFLD, where oxidative stress plays a central mechanistic role. Clinical guidelines from gastroenterological associations have considered vitamin E in the management of NASH in non-diabetic adults, though its effects are context- and dose-specific and not without controversy.
A scientific review notes clinical evidence of effects from fish oil on detoxification pathway activity. Omega-3 fatty acids (EPA and DHA from marine sources) have been studied for their anti-inflammatory effects and their role in reducing hepatic fat accumulation in NAFLD, with multiple meta-analyses showing modest reductions in liver fat assessed by imaging.
Quercetin is a flavonoid present in many fruits, vegetables, and grains that modulates CYP450 enzymes in Phase I and is a potent inducer of Phase II enzymes (GST and NAD(P)H quinone oxidoreductase-1 (NQO1)) and the Nrf2 pathway in Phase III. Evidence remains largely preclinical, with human data on liver-specific detoxification enzyme induction limited to small intervention studies.
Citrus fruits, garlic, beets, leafy greens, and berries supply flavonoids, vitamin C, and polyphenols that further support Phase I and Phase II detox processes. In contrast, diets high in refined carbohydrates, trans fats, and processed meats contribute to oxidative stress, inflammation, and steatosis, thereby taxing the liver. Studies have shown that patients with NAFLD who shift to a Mediterranean-style or anti-inflammatory diet rich in fiber, antioxidants, and healthy fats demonstrate significant reductions in liver fat content and ALT levels.
An umbrella review of dietary interventions found that dietary patterns including high-protein, Mediterranean, and calorie-restriction diets may reduce liver enzymes; however, the evidence quality was generally weak given the risk of bias, heterogeneity, and imprecision.
Dietary fiber (DF) intake elicits a wide range of physiologic effects. DFs can greatly alter the gut milieu by affecting the gut microbiome, which in turn influences the gut barrier, gastrointestinal immune and endocrine responses, and nitrogen cycling and microbial metabolism. Adequate fiber supports bile acid sequestration in the gut, promotes regular bowel transit of conjugated metabolites, and supports a microbiome environment that reduces the production of hepatotoxic secondary metabolites such as lipopolysaccharides.
High fructose consumption is a well-known risk factor for NAFLD/NASH. In a study of young nonobese individuals without metabolic risk factors, the single independent factor for the detection of NAFLD was higher juice and soft drink intake contributing up to a four-fold increase in risk of NAFLD compared with individuals consuming less sugar-sweetened beverages.
Physical activity, aerobic and anaerobic exercise, were associated with reduction in liver fat and other metabolic benefits independent of weight loss. Diet and exercise combined are superior to these interventions alone in improving liver enzymes and HOMA-IR, according to a systematic review and meta-analysis on lifestyle changes in NAFLD.
Good hydration is important for most basic physiological functions of the liver. Sufficient hydration is required to promote blood circulation and to dissolve nutrients. An adequate intake of water encourages metabolism and facilitates biliary secretion, supporting the elimination of water-soluble conjugates produced by Phase II reactions. This effect is physiologically plausible, though the specific dose-response relationship between water intake and detoxification efficiency in humans is not rigorously defined.
A 2015 review concluded that there was no compelling research to support the use of "detox" diets for weight management or eliminating toxins from the body. A 2017 review said that juicing and "detox" diets can cause initial weight loss because of low caloric intake, but they tend to lead to weight gain once a person resumes a normal diet. There have been no studies on the long-term effects of "detoxification" programs.
These methods are based on the idea that reducing caloric and metabolic load gives the liver a "rest" and allows it to focus on clearing toxins. While intermittent fasting has been shown to improve insulin sensitivity, promote autophagy, and reduce hepatic fat accumulation, prolonged fasting or mono-diets such as juice-only cleanses can backfire. Juice fasts, in particular, often lack essential amino acids required for Phase II detoxification and may contain excessive sugar, especially fructose, which increases hepatic burden.
Although some fasting programs are advertised with "detoxification" claims, other fasting programs — including intermittent fasting and periodic fasting — are being researched for health promotion, disease prevention, improved aging, and in some cases weight loss. But there are no firm conclusions about their effects on human health.
Many over-the-counter liver cleanse products have not been tested, approved, or regulated by authorities. There is no proof of their effectiveness and in fact they may be harmful to the body. Case reports in the medical literature document hepatotoxicity from products marketed for liver detoxification. Such cases highlight the importance of considering herbal supplements in the differential for fulminant hepatitis and call for better public education and controlled trials to evaluate and regulate such natural products. The FDA and Federal Trade Commission have taken action against several companies selling detox/cleansing products because they contained hidden ingredients, were marketed using false claims that they could treat serious diseases, or were marketed for unapproved uses.
The liver's endogenous biotransformation system — involving Phase I CYP450 functionalization, Phase II conjugation (via glutathione, glucuronide, sulfate, and amino acid pathways), and Phase III transport/elimination — is a well-characterized physiological process operating continuously without external "cleansing." The knowledge of effects of various food plants on liver health is still insufficient. Traditional methods and experiences about the use of food plants for treatment of liver disease must be validated by admissible evidence obtained on the basis of modern technology.
The overall quality of evidence across the nutritional and botanical literature remains limited. A 2023 umbrella review evaluated 40 meta-analyses on natural products, dietary supplements, and dietary patterns; the overall methodological quality of the included studies was relatively poor. Results indicated that positive effects were observed for nigella sativa, garlic, artichoke, curcumin, silymarin, vitamin E, vitamin D, L-carnitine, propolis, and polyunsaturated fatty acids on certain liver enzymes. This umbrella review suggests that natural products and dietary interventions have beneficial therapeutic effects on liver enzyme levels, but further clinical trials are necessary to establish the effectiveness of supplements that reduce liver enzymes.
Lifestyle changes are the primary approaches for the prevention and treatment of liver diseases. Since ancient times, herbals have also been used for preventive and therapeutic purposes because of their anti-apoptotic, anti-inflammatory, and antioxidant effects. The integration of well-studied dietary patterns, avoidance of known hepatotoxic exposures (excess alcohol, fructose, hepatotoxic supplements), adequate protein to support Phase II reactions, regular physical activity, and judicious evaluation of specific botanicals with evidence of hepatoprotective potential represents the framework most consistently supported by available science.
Acacia gum has demonstrated hepatoprotective activity in human trials: a Phase II RCT in rheumatoid arthritis patients showed that 30 g/day for 12 weeks significantly reduced liver enzymes and improved albumin levels. Antioxidant enzyme activity (superoxide dismutase, catalase, glutathione peroxidase) in liver tissue is also increased by gum arabic supplementation, as documented in a systematic review of clinical trials.
Adzuki bean extract protects against acetaminophen- and D-galactosamine-induced liver damage in rats by upregulating hepatic antioxidant enzymes (glutathione peroxidase, glutathione reductase, SOD). Multiple HFD studies show adzuki bean reduces hepatic steatosis, ALT, and AST. Animal evidence is consistent; human liver data are limited.
Agrimony has the strongest human evidence of any of its indications for liver health. A 2018 randomised, double-blind, placebo-controlled trial (Cho et al.) in 69 subjects with elevated ALT found significant reductions in ALT and AST after 8 weeks of agrimony extract. Traditional use for liver conditions is extensively documented across European folk medicine.
Hepatoprotective activity of ajwain extract has been demonstrated in animal models, including protection against paracetamol-induced liver damage. This effect has been consistently cited in pharmacological reviews as one of the key scientifically characterized properties of T. ammi. No human liver studies exist.
A. muciniphila reduces hepatic steatosis, liver enzyme levels (ALT, AST), and inflammation via the gut-liver axis in preclinical NAFLD/NASH models. In the 2019 human RCT, A. muciniphila supplementation reduced blood markers of liver dysfunction versus placebo. The bacterium reinforces the intestinal barrier to limit LPS translocation to the liver via the portal vein, its primary hepatoprotective mechanism. Specific liver detoxification enzymes have not been studied.
Alpha-lipoic acid is a potent endogenous antioxidant that scavenges free radicals, regenerates vitamins C and E, and increases hepatic glutathione levels. Animal studies demonstrate hepatoprotective effects against NAFLD, acetaminophen toxicity, and CCl4-induced liver damage. Small human clinical studies report improvements in liver enzyme levels and oxidative stress markers in NAFLD and hepatitis patients.
Allicin is the primary bioactive organosulfur compound from garlic demonstrating hepatoprotective effects via NLRP3 inflammasome suppression, phase II enzyme induction, and antioxidant activity. A PMC-indexed hepatoprotection review specifically documents allicin from Allium sativum as exhibiting hepatoprotective activity through suppression of NLRP3 inflammasome activation and reduction of caspase-1 and IL-1β in hepatocytes.
Isoquercitrin (AGIQ's direct metabolic precursor) has demonstrated hepatoprotective and antioxidant effects in liver cell models via AMPK/YAP signaling, reducing ROS and protecting hepatocytes from oxidative damage. Animal studies show AGIQ suppresses hepatic preneoplastic lesion development. Preclinical hepatocellular health benefits of AGIQ have been noted in multiple animal experiments.
Andrographis paniculata has extensive use in Ayurvedic, Chinese, and Southeast Asian traditional medicine for liver protection, hepatitis, and jaundice. Scientific studies demonstrate andrographolide prevents hepatotoxin-induced liver injury by reducing oxidative stress, elevating glutathione, and inhibiting inflammatory mediators. Animal studies confirm hepatoprotective and antioxidant action against BHC and CCl4-induced liver damage.
Andrographolide is the primary active diterpenoid from Andrographis paniculata demonstrating documented hepatoprotective effects via NF-κB inhibition, Nrf2 activation, glutathione restoration, and antioxidant enzyme upregulation. Preclinical studies confirm it prevents hepatotoxin-induced liver injury. Its hepatoprotective activity is specifically cited in peer-reviewed research and is the basis for Andrographis paniculata's liver-support classification.
Multiple clinical trials in NAFLD patients show annatto-derived delta-tocotrienol significantly reduces liver enzymes (ALT, AST), fatty liver index, and degree of hepatic steatosis on ultrasound. A 24-week RCT (n=71) using 600 mg/day demonstrated improvements in liver biomarkers, HOMA-IR, and steatosis grade. Animal data also confirm bixin's hepatoprotective effect against toxic insult.
Aronia melanocarpa extracts have demonstrated hepatoprotective activity in multiple animal models, including against carbon tetrachloride and alcohol-induced liver injury, via Nrf2 signaling and antioxidant mechanisms. A human pilot trial found reductions in liver enzyme (ALAT) levels following 6 weeks of Aronia extract supplementation.
Artichoke leaf extract (Cynara scolymus) demonstrates antioxidant, choleretic, and hepatoprotective effects validated in both animal studies and human RCTs. A double-blind RCT in 60 NASH patients showed significant improvement in liver enzymes (ALT, AST) and lipids with 2700 mg/day extract. A 2018 RCT in 100 NAFLD patients showed increased hepatic blood flow and reduced liver enzymes, bilirubin, and triglycerides with 600 mg/day. Traditional use as a liver tonic and cholagogue dates back centuries in Mediterranean herbal medicine.
Ashitaba has one randomized double-blind human trial (Noh et al., J Med Food, 2015) showing improvement in some liver function markers in habitual alcohol drinkers. Animal studies further support hepatoprotective effects, and a metabolic syndrome pilot confirmed hepatoprotective activity. Ashitaba has also traditionally been used to support liver function.
A 2026 systematic review of human trials suggests astaxanthin's primary organ for insulin sensitization may be the liver, with improvements in hepatic insulin resistance index observed. Animal studies confirm protection of liver tissue in PCOS models, and preclinical data show ASX reduces non-alcoholic fatty liver markers. Limited but emerging human evidence supports hepatic benefit.
Astragalus and its constituent AS-IV have well-documented hepatoprotective activity in preclinical models, protecting against chemical liver injury, fibrosis, and metabolic liver disease. Traditional Chinese medicine has used astragalus for liver diseases including hepatitis. NIH LiverTox confirms hepatoprotective activity in animal models and traditional clinical use for hepatitis.
Atractylodes macrocephala polysaccharides have demonstrated hepatoprotective effects in drug-induced and diet-induced liver injury models, reducing ALT/AST, oxidative stress markers, and inflammatory cytokines. The herb has a documented traditional association with liver and spleen meridian function in TCM.
Bamboo stem and leaf extracts demonstrate hepatoprotective effects through activation of the Nrf2 antioxidant pathway and modulation of hepatic xenobiotic biotransformation enzymes. Animal studies show bamboo extract reduces hepatic fat content, oxidative liver damage, and acute-alcohol-induced liver injury. TCM uses bamboo preparations to 'clear heat' and detoxify.
Banaba leaf extract exhibits hepatoprotective activity in animal and zebrafish models, reducing markers of liver injury, preventing fatty liver changes, and lowering hepatic lipid accumulation. Corosolic acid in obese mice produced a major reduction in hepatic lipids and prevented hepatic steatosis. No dedicated human liver detoxification clinical trials exist.
Barley sprout extract has been evaluated in human RCTs for its ability to protect against alcohol-induced liver oxidative stress. It activates Nrf2 antioxidant pathways, restores glutathione, and reduces liver enzyme markers in habitual drinkers with fatty liver.
A small human RCT (n=44) found bayberry juice (250 mL twice daily, 4 weeks) reduced oxidative stress, inflammatory, and apoptotic markers in young adults with nonalcoholic fatty liver disease. Drugs.com and a PMC review confirm one small clinical study showed protective liver effects. Myricitrin's promotion of bile flow has been noted in traditional herbalism, though not confirmed in humans.
Bee pollen exhibits consistent hepatoprotective effects in multiple animal models, protecting against chemical-induced liver damage, reducing liver enzyme elevations (AST, ALT), and reducing hepatic steatosis. In vitro studies confirm protection of liver cell lines (HepG2, Hepa1-6) from oxidative and lipotoxic damage.
Betaine from beetroot supports hepatic methylation and protects against nonalcoholic fatty liver disease (NAFLD/MASLD) and alcoholic liver disease by preserving the methionine metabolic cycle. Betanin also reduces hepatic oxidative stress and lipid peroxidation in preclinical models, with limited human clinical data.
Multiple preclinical studies demonstrate that T. bellirica extracts and its constituent ellagic acid exert hepatoprotective effects, reducing liver enzyme markers and oxidative stress in drug-induced hepatotoxicity models in rodents. Effects are comparable to silymarin as a reference hepatoprotective standard. Traditional use for liver protection is documented across Ayurveda, Tibetan, and traditional Chinese medicine systems.
Berberine, an isoquinoline alkaloid found in goldenseal, barberry, and Coptis, demonstrates hepatoprotective effects in animal models of CCl4-induced acute hepatotoxicity, significantly reducing ALT, AST, and liver oxidative damage. Clinical trial reviews confirm berberine reduces liver enzymes in NAFLD and liver disease. It also activates AMPK, reducing hepatic fat accumulation.
Betaine is an established methyl donor for hepatic one-carbon metabolism, supporting S-adenosylmethionine (SAM) synthesis and thereby facilitating hepatic methylation, lipid export, and glutathione production. Clinical evidence in NASH/NAFLD is mixed: an open-label cohort study in 35 NASH patients (20 g/day, 1 year) showed improved liver enzymes and histology, while a subsequent RCT found no improvement in hepatic steatosis versus placebo. Betaine is FDA-approved (Cystadane) for homocystinuria to support hepatic homocysteine clearance.
The liver uses bile salt synthesis and secretion as its primary mechanism for eliminating cholesterol and excreting lipophilic waste products (bilirubin, drug metabolites, xenobiotics) into the intestinal lumen for fecal excretion. Bile salt transport proteins (BSEP, MRP2) drive biliary secretion of conjugated toxins. Impaired bile salt export (cholestasis) causes hepatotoxic accumulation of bile constituents. UDCA is used clinically to reduce bile toxicity in cholestatic conditions.
A systematic review of 4 RCTs in NAFLD found N. sativa significantly reduced hepatic steatosis grade and serum liver enzymes (ALT, AST) in three of four trials. The 2025 meta-analysis of 82 RCTs confirmed significant improvements in ALT, AST, and ALP with N. sativa supplementation.
Piperine has demonstrated hepatoprotective activity by reducing lipid peroxidation, preventing GSH depletion, and inhibiting hepatotoxin-induced enzyme leakage in animal models. A human pilot study found piperine-curcumin-taurine combination benefited hepatocellular carcinoma patients. Traditional medicine systems have long used black pepper for liver and biliary complaints.
LBPs are hepatoprotective across multiple liver injury models including alcohol-induced, carbon tetrachloride-induced, NAFLD, heavy metal, and cadmium-induced injury. Mechanisms include activation of PPAR-α and inhibition of NLRP3/Caspase-1–mediated pyroptosis. Traditional Chinese medicine canonically lists boxthorn as a liver-nourishing herb.
Broccoli sprout extract rich in sulforaphane has shown significant improvement in liver function markers (ALT, AST, GGT) in human RCTs involving subjects with NAFLD and hepatic abnormalities. Sulforaphane induces Nrf2-regulated phase II detoxification enzymes in the liver, reducing oxidative stress and protecting hepatocytes.
Brussels sprouts upregulate hepatic Phase I and Phase II detoxification enzymes (cytochrome P450s, glutathione S-transferases) via I3C/DIM and isothiocyanate-driven AhR and Nrf2 signaling. Human studies confirm increased blood and colonic GST activity after Brussels sprouts consumption. I3C is specifically noted by Memorial Sloan Kettering to stimulate detoxifying enzymes in the gut and liver.
Burdock root has demonstrated hepatoprotective effects in multiple animal studies, protecting the liver from damage caused by alcohol, carbon tetrachloride, acetaminophen, cadmium, and lead. A 2023 laboratory study found burdock root reduced fat accumulation in liver cells (hepatic steatosis). PMC reviews confirm antioxidant-mediated hepatoprotection. Human clinical data remain limited.
Sulforaphane from cabbage activates hepatic Nrf2 signaling, upregulating Phase II detoxification and antioxidant enzymes in the liver. Cabbage juice has been shown to attenuate liver enzyme elevations (ALT, AST, ALP) in a rodent liver-damage model. I3C/DIM from cabbage also modulates hepatic CYP enzymes involved in hormone and xenobiotic metabolism.
Hepatoprotective activity of C. crista has been demonstrated in multiple animal studies, including protection against carbon tetrachloride (CCl4)- and iron-overload-induced liver toxicity. A PMC-indexed study confirmed hepatoprotection via antioxidant and iron-chelating mechanisms.
Capsanthin protects against hepatic steatosis (fatty liver) in NAFLD mouse models, reducing liver lipid accumulation, hepatic enzyme markers (ALT, AST), and modulating fatty acid oxidation gene expression. These effects suggest a role in supporting liver metabolic function.
Green cardamom has been directly studied in NAFLD patients in double-blind RCTs. A published RCT (n=87) using 1,500 mg/day for 3 months found cardamom increased serum Sirtuin-1 and reduced liver-related inflammatory markers and liver enzymes. Animal and cell studies further support hepatoprotective effects via Nrf2/HO-1/NQO-1 antioxidant pathway activation.
Carrot bioactives support hepatic detoxification through antioxidant protection against chemical-induced hepatotoxicity, modulation of liver enzyme profiles, and upregulation of Nrf2-mediated phase-2 detoxifying enzymes via falcarinol and falcarindiol. Evidence is primarily animal-based.
BCP exerts hepatoprotective effects in multiple rodent liver injury models, including alcoholic steatohepatitis, NAFLD, fibrosis, and hepatotoxin exposure, by reducing hepatic lipid accumulation, inflammation, and oxidative stress via CB2 and PPAR receptors.
EGCG and green tea catechins have been extensively studied for protective effects against non-alcoholic fatty liver disease (NAFLD), reducing liver triglyceride accumulation, oxidative stress, and inflammation in the liver. A systematic review found catechin supplementation plays a significant role in regulating lipid and glucose metabolism and reducing pro-inflammatory liver damage pathways.
Sulforaphane from cauliflower is a well-characterized inducer of hepatic phase II detoxification enzymes (glutathione-S-transferases, glucuronosyltransferases, NQO1) via the Nrf2/ARE pathway. It also activates ALDH2 to facilitate acetaldehyde metabolism and reduces inflammatory infiltration and hepatic fibrosis. Preclinical evidence is extensive; human choline-related data also supports liver fat metabolism.
Hepatoprotective activity of A. aspera has been demonstrated in multiple animal studies, including protection against chemical-induced liver damage. A 2015 PubMed-indexed Arch Med Sci study found saponins reduced hepatic lipid peroxidation and liver weight in high-cholesterol rats.
Chen Pi flavonoids hesperidin and naringin protect the liver from chemically induced injury by activating the NRF2 antioxidant pathway, inhibiting AKT1 phosphorylation, and reducing hepatic lipid accumulation. Systems pharmacology studies confirm multi-target hepatoprotective activity.
A rodent study demonstrated that a water-soluble polysaccharide fraction of S. media reduced markers of liver damage (ALT, AST, bilirubin) in CCl4-induced hepatitis. Traditional use of chickweed for liver 'heat-clearing' also exists. No human studies have been conducted.
Chicory (Cichorium intybus) has traditional use in Unani, Ayurvedic, and European herbal medicine as a liver tonic and cholagogue. Scientific studies confirm hepatoprotective effects via inulin-mediated prebiotic effects, antioxidant activity, and anti-inflammatory properties. A 2024 clinical trial review confirmed chicory reduces liver enzymes in liver disease.
Danshen has demonstrated hepatoprotective effects in both clinical trials and preclinical studies, covering non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease, and hepatic fibrosis. A meta-analysis of 8 RCTs in NAFLD patients showed significant reductions in liver transaminases. Its mechanisms include antioxidant activity, anti-fibrotic effects, and regulation of lipid metabolism.
Chlorella, a unicellular green algae, has demonstrated hepatoprotective effects in clinical and preclinical studies, with a 2024 clinical trials review confirming it reduces liver enzymes in liver disease patients. Its hepatoprotective activity relates to its antioxidant capacity, chlorophyll content, and ability to bind and facilitate elimination of toxins and heavy metals from the liver.
Chlorophyll and its derivatives (chlorophyllin) bind lipophilic carcinogens and aflatoxins in the GI tract, reducing their absorption and hepatic exposure. A well-designed crossover clinical trial in Qidong, China found chlorophyllin supplementation significantly reduced aflatoxin-DNA adduct biomarkers in humans, providing direct evidence of liver carcinogen reduction. Traditional food use of chlorophyll-rich plants for liver health spans multiple cultures.
Chlorophyllin intercepts dietary hepatotoxic carcinogens (particularly aflatoxin-B1) in the GI tract before they reach the liver, with a 55% reduction in DNA adduct biomarkers demonstrated in a landmark PNAS RCT (n=180). In mouse models of hepatic fibrosis, oral chlorophyllin attenuated liver inflammation and reduced fibrosis markers by modulating gut-liver signaling. The human evidence relates to carcinogen interception rather than direct hepatic enzyme modulation.
Multiple animal studies show chokeberry extract protects against liver injury, reduces hepatic lipid accumulation (steatosis), and suppresses serum transaminases, while increasing liver antioxidant capacity. The hepatoprotective effect has been documented in models of alcoholic liver injury, carbon tetrachloride toxicity, and non-alcoholic fatty liver disease. Direct human liver clinical trial evidence is limited.
Choline is an essential nutrient whose deficiency directly causes hepatic steatosis (fatty liver), demonstrated in controlled human depletion studies. It is required for VLDL assembly and hepatic fat export, and supports phase II liver detoxification via methylation pathways. Adequate choline intake prevents liver damage and supports liver regeneration, documented in Journal of Nutrition studies.
Chrysanthemum extracts demonstrate hepatoprotective activity in multiple animal studies, reducing markers of liver injury and oxidative stress. In TCM, chrysanthemum 'clears the liver' and is prescribed for liver-heat conditions. A 2025 Scientific Reports study showed C. morifolium extract ameliorated fatty liver and improved lipid and liver function markers in a mouse model.
Chrysin has well-documented hepatoprotective properties in animal models, counteracting hepatotoxicity induced by chemical agents (CCl4, d-galactosamine, paracetamol), alcohol, and metabolic insults including NAFLD and liver fibrosis. Mechanisms include restoring antioxidant enzymes, reducing lipid peroxidation, and suppressing inflammatory cytokines. No human liver trials have been published.
Preclinical studies demonstrate that eugenol-rich clove fractions reverse biochemical and histopathological signs of liver injury in animal models of cirrhosis, fatty liver, and toxic hepatopathy. Clove polyphenols modulate oxidative stress and inflammatory markers in hepatic tissue.
Coix seed extracts reduce hepatic fat accumulation, oxidative stress, and liver enzyme elevations in nonalcoholic fatty liver disease (NAFLD) animal models. Multiple studies show liver-protective effects via AMPK pathway activation and lipogenesis inhibition.
Collard greens contain glucosinolates and methyl cysteine sulfoxides that activate hepatic phase II detoxification enzymes (glutathione S-transferases), facilitating conjugation and elimination of carcinogens and xenobiotics. Collards also boost glutathione — the body's primary antioxidant — which is required for liver neutralization of toxins. A 12-week RCT in 391 adults consuming cruciferous vegetables showed significantly increased urinary excretion of benzene carcinogens compared to placebo.
Coptis chinensis and its berberine component have documented hepatoprotective effects in animal models, reducing liver injury markers (ALT, AST), improving hepatic lipid metabolism, and used in TCM formulas for liver congestion and 'clearing heat in the liver.' Clinical evidence for NAFLD shows promise.
CoQ10 is naturally concentrated in the liver, where it supports mitochondrial energy production and acts as a lipid-soluble antioxidant. Systematic reviews and meta-analyses of RCTs indicate CoQ10 supplementation modestly reduces liver enzymes (ALT and AST) in NAFLD patients. Evidence for broader 'detoxification' is limited to hepatoprotective effects against drug-induced and metabolic liver injury.
Cordyceps militaris exhibits hepatoprotective activity in multiple animal models of liver injury, including NAFLD and NASH, reducing liver enzymes (ALT, AST), hepatic lipid accumulation, triglycerides, and oxidative stress. It inhibits liver fibrosis and reduces inflammatory cytokines in hepatic tissue. Human safety data from NIH LiverTox confirm no elevation in liver enzymes in adults taking Cordyceps extracts, but human therapeutic trials for liver disease are lacking.
Animal studies consistently demonstrate hepatoprotective effects of corn silk extract, including reductions in liver enzymes (AST, ALT), improvements in liver histopathology, and protection against chemical-induced hepatotoxicity. A 2024 mouse study showed corn silk extract ameliorates fatty liver disease by modulating gut microbiota and liver metabolites.
Cucumber extracts have demonstrated hepatoprotective activity in multiple animal studies, protecting against chemically induced liver injury (cumene hydroperoxide, carbon tetrachloride) and normalising liver enzymes and oxidative stress markers in diabetic models. The ScienceDirect Cucumis genus review identifies organ-protective activities as validated pharmacological properties.
Cumin stimulates hepatic bile secretion significantly (bile volume increased 25%, bile acid output up to 70% in animal studies), which aids fat digestion and supports liver function. One RCT specifically studied cumin in nonalcoholic steatohepatitis (NASH). Traditional use for jaundice and liver function is documented.
Curcumin, the primary bioactive polyphenol from turmeric, exerts hepatoprotective effects through antioxidant, anti-inflammatory (NF-κB inhibition), and antifibrotic (TGF-β/Smad modulation) mechanisms. Multiple RCTs and meta-analyses demonstrate significant reductions in ALT and AST in MAFLD patients. A 72-week RCT showed MASH resolution in 62% of patients receiving phospholipid curcumin 2g/day.
D-alpha tocopherol is the most extensively studied antioxidant in non-alcoholic fatty liver disease (NAFLD/NASH), with multiple RCTs demonstrating reductions in liver enzymes, steatosis, hepatic inflammation, and ballooning degeneration. The NIH LiverTox resource confirms its hepatoprotective role in inflammatory liver disease.
D-glucarate (calcium-D-glucarate) inhibits beta-glucuronidase, an enzyme produced by gut bacteria that deconjugates glucuronide-conjugated toxins, hormones, and carcinogens, allowing their reabsorption. This supports phase II hepatic glucuronidation, enhancing elimination of toxins and hormones. It is specifically cited in liver detoxification databases alongside milk thistle, NAC, and other hepatoprotective agents.
Dandelion (Taraxacum officinale) has extensive traditional use in TCM and European herbalism as a liver tonic and bile-stimulating herb. Preclinical studies demonstrate hepatoprotective effects against alcohol, carbon tetrachloride, and paracetamol-induced liver injury through antioxidant and anti-inflammatory activity. Clinical human evidence is limited and emerging; animal studies are well-documented.
Delta-tocopherol and its tocotrienol counterpart have been studied in human clinical trials for non-alcoholic fatty liver disease (NAFLD), showing significant improvement in hepatic steatosis, oxidative stress, and insulin resistance. A 48-week RCT found both δ-tocotrienol and α-tocopherol equally improved fatty liver index and liver-to-spleen ratio, with δ-tocotrienol more potent in reducing inflammation and apoptosis. Vitamin E forms reduce oxidative stress and fat accumulation in hepatocytes.
Diindolylmethane (DIM) is the primary active metabolite of indole-3-carbinol from cruciferous vegetables, acting as an Nrf2 and AhR ligand inducing hepatic phase I and II detoxification enzymes. It promotes favorable estrogen and xenobiotic metabolism in the liver. Scientific research documents its role in upregulating GST, UGT, and CYP1A-mediated hepatic biotransformation relevant to liver detox.
Diosgenin and dioscin from Dioscorea species demonstrate hepatoprotective effects in multiple animal and cell studies, reducing oxidative stress, liver fibrosis, and inflammatory cytokines. A 2023 PMC literature review catalogues mechanisms including antioxidant activity and gut microbiota modulation. No human liver trials exist.
EGCG is the principal hepatoprotective polyphenol in green tea, demonstrating antioxidant, anti-inflammatory, antiviral, and anti-fibrotic activity in the liver. Research confirms EGCG inhibits hepatitis B and C viral replication, reduces hepatic lipid accumulation, and activates Nrf2-mediated phase II detoxification pathways. Clinical trial reviews confirm it reduces liver enzymes in liver disease.
E. littorale demonstrates hepatoprotective and hepatomodulatory activity in multiple preclinical models including paracetamol-, D-galactosamine-, ethanol-, and CCl4-induced hepatotoxicity. Swertiamarin is identified as the primary hepatoprotective phytochemical, with mechanisms including antioxidant enzyme upregulation, ROS reduction, and normalization of hepatic biomarker enzymes.
Eucommia extracts show hepatoprotective effects in multiple preclinical models. In CCl4-induced chronic hepatotoxicity rats, leaf extract reduced liver injury enzymes (ALT, LDH, ALP), increased glutathione and antioxidant enzymes, and reduced histopathological liver lesions. Network pharmacology studies suggest mechanisms involving anti-oxidative, anti-inflammatory, and cytoprotective targets.
Fennel essential oil demonstrates hepatoprotective effects in preclinical models, reducing liver enzyme markers (AST, ALT, ALP, bilirubin) following chemical-induced hepatotoxicity. Traditional medicine also classifies fennel as hepatoprotective. Human liver-specific clinical trials are not available.
Fenugreek exhibits hepatoprotective effects supported by animal model studies and emerging clinical data; it reduces hepatic oxidative stress, modulates bile composition, and may protect against liver injury. The NIH LiverTox database confirms no clinically apparent liver toxicity and documented preclinical hepatoprotective activity.
Animal studies consistently demonstrate hepatoprotective activity of F. asafoetida extracts, including reduction of elevated liver enzymes (ALT, AST, ALP) in models of chemical-induced hepatotoxicity. A 2025 PMC review specifically examined asafoetida's protective effects on the liver against formaldehyde-induced damage.
Ferulic acid has demonstrated hepatoprotective activity against drug-induced liver injury (acetaminophen, methotrexate, antituberculosis drugs, cisplatin), liver fibrosis, and hepatocyte apoptosis in multiple preclinical studies. Clinical trials have shown FA can improve markers in liver cirrhosis. It reduces plasma ALT, AST, and ADH activity, protects hepatocyte structure, and reduces oxidative stress-mediated hepatotoxicity.
Fisetin exerts hepatoprotective effects via NF-κB, Nrf2, AMPK, and SIRT1 pathway modulation, reducing hepatic inflammation, oxidative stress, steatosis, and fibrosis in preclinical models. A 2025 PMC review identified its potential in intestinal failure-associated liver disease.
Forsythia suspensa has documented hepatoprotective activity, with multiple preclinical studies identifying liver-protective compounds including new iridoid glycosides. Forsythoside A exerts hepatoprotective effects via antioxidant mechanisms including MDA clearance. Animal models show it can prevent fulminant hepatitis. Human clinical trials are lacking.
Poria cocos polysaccharides have demonstrated hepatoprotective effects in multiple preclinical models, reducing ALT, AST, and inflammatory markers in alcohol-induced and LPS/D-galactosamine-induced liver injury. P. cocos triterpenoids also promote reverse cholesterol transport and reduce liver lipid deposition. These effects are mediated via PI3K/AKT/NF-κB and antioxidant pathways.
Ganoderma lucidum has well-documented hepatoprotective properties supported by both preclinical and human evidence. A double-blind crossover RCT in 42 healthy volunteers showed significant improvements in antioxidant capacity and liver enzyme markers, with reversal of mild fatty liver on ultrasound.
Gardenia jasminoides has extensive preclinical and some clinical evidence for hepatoprotective activity. A clinical study demonstrated that crude gardenia extract rapidly lowers serum bilirubin and transaminase levels in jaundice-induced acute hepatitis. Geniposide protects against liver injury from acetaminophen, CCl4, alcohol, ischemia-reperfusion, sepsis, and cholestasis, via anti-inflammatory and antioxidant mechanisms.
Gardenia jasminoides has extensive preclinical evidence for hepatoprotective and cholagogic (bile-promoting) effects. Key constituents geniposide and crocins protect against chemical-induced liver injury (CCl4, ANIT, acetaminophen, alcohol), reduce ALT/AST enzyme elevations, and promote bile flow. It is a core herb in the TCM liver-jaundice formula Yinchenhaotang, which has clinical use in Japan and China.
Garlic (Allium sativum) and its organosulfur compounds (allicin, S-allylcysteine, diallyl sulfide) demonstrate hepatoprotective effects in multiple preclinical studies, reducing CCl4 and alcohol-induced liver injury through antioxidant, anti-inflammatory, and phase II enzyme-inducing mechanisms. S-allylcysteine specifically suppresses NLRP3 inflammasome activation in hepatocytes. Traditional use as a liver-supportive food and medicine spans multiple cultures.
Garlic organosulfur compounds upregulate hepatic detoxification enzymes including glutathione peroxidase and support liver function in clinical settings. An RCT systematic review (PMC10292950) found garlic supplementation improves liver enzyme levels and reduces steatosis in NAFLD patients. Mechanistic evidence for garlic-supported hepatic phase-II detoxification is well established.
Gentian root has documented hepatoprotective activity in animal models, with extracts of G. asclepiadea significantly reducing serum transaminases (ALT, AST), alkaline phosphatase, and bilirubin in CClâ‚„-induced liver injury, while raising glutathione, catalase, and superoxide dismutase. G. manshurica protected against alcohol-induced fatty liver and hepatic steatosis in rodents. Traditional use as a liver tonic is codified in Commission E and the WHO monograph.
Multiple Gentiana species including G. lutea exhibit hepatoprotective effects in animal models, reducing liver enzyme elevations (AST, ALT, ALP), inhibiting lipid peroxidation, and augmenting antioxidant defenses (SOD, CAT, GSH). Gentiopicroside and swertiamarin are the primary hepatoprotective constituents. TCM has used gentian for liver-related diseases for centuries. Human clinical data are absent; evidence is preclinical.
Gentiana macrophylla exhibits hepatoprotective activity in preclinical models of liver injury. Root extracts and the constituent gentiopicroside protect against CCl4-induced, ethanol-induced, and immune-mediated liver damage, reducing ALT, AST, MDA, and restoring hepatic tissue structure. Gentiopicroside also modulates lipid metabolism via the LKB1/AMPK pathway, relevant to alcoholic and metabolic liver disease.
Ginger (Zingiber officinale) and its active constituents (gingerols, shogaols) demonstrate hepatoprotective effects in multiple animal studies via antioxidant and anti-inflammatory mechanisms, reducing liver enzyme elevations and oxidative liver damage. Traditional use in Ayurvedic, Chinese, and Arab medicine for digestive and liver conditions is extensively documented. Human clinical data specifically for liver detox are limited.
Ginseng has been extensively studied for hepatoprotective effects. A 2020 meta-analysis of 14 RCTs (n=992) found no significant change in standard liver enzymes (ALT, AST, GGT, ALP) at conventional doses in healthy individuals, but a 2025 systematic review highlights ginseng's multi-target mechanisms in non-alcoholic fatty liver disease (NAFLD), including reduction of lipid accumulation and oxidative stress. Preclinical and some clinical evidence supports hepatoprotective activity in those with liver disease, though robust human trial data remain limited.
Glycine is a direct substrate for hepatic glutathione synthesis (the cell's primary detoxifying antioxidant) and performs phase II conjugation of potentially toxic endogenous and xenobiotic metabolites. Human studies in obese individuals show glycine supplementation corrects glycine deficiency and restores the glycine conjugation detoxification pathway. Animal studies further show glycine protects hepatocytes from ischemic and toxic injury via cytoprotective chloride channel activation.
Goji berry has documented hepatoprotective effects in animal models and a human clinical study. A 45-day study in metabolic syndrome patients showed significant reduction in liver transaminases (AST/ALT). Animal research demonstrates protection against alcohol-induced fatty liver, carbon tetrachloride toxic hepatitis, and acute alcohol-induced liver injury, partly via gut microbiota modulation.
Amla has well-documented hepatoprotective activity. PMC literature reviews cite its ability to modulate oxidative markers and enhance endogenous antioxidant defenses in hepatocyte cell lines. Animal studies show reversal of liver damage, and a Ayurvedic tradition of liver tonic use is reinforced by modern mechanistic research.
Preliminary clinical evidence shows GSE supplementation benefits liver health, particularly in non-alcoholic fatty liver disease (NAFLD). A double-blind RCT in 50 NAFLD patients treated with 520 mg/day GSE found improvements in glycemic status, lipid profile, blood pressure, and liver enzymes. Animal studies confirm hepatoprotective effects against steatosis progression. Evidence is preliminary and more large-scale RCTs are needed.
Grapefruit's flavonoids naringenin and naringin have documented protective effects on the liver, including reduction of fat accumulation, oxidative stress, and inflammatory signaling in NAFLD models. Grapefruit juice inhibits hepatic CYP450 enzymes, modulating phase I liver detoxification. Clinical trial protocols for naringenin in NAFLD have been published, though completed human RCTs are limited.
Hepatoprotective activity is among the most deeply studied properties of green chiretta. Preclinical studies across multiple hepatotoxicity models consistently show restoration of liver enzymes (ALT, AST, ALP) and antioxidant defense; early clinical data support benefit in liver function in patients with gastrointestinal and liver ailments. Traditional use for jaundice and liver disorders is millennia-old.
Green tea and its primary polyphenol EGCG (epigallocatechin gallate) have demonstrated hepatoprotective effects in preclinical studies and clinical trials, reducing liver enzyme levels and liver fat in NAFLD. EGCG inhibits hepatitis B and C viral replication, reduces hepatic inflammation, and supports phase II detoxification enzyme activity. A comprehensive 2024 clinical trial review confirmed green tea caused a decrease in liver enzymes.
GS demonstrates hepatoprotective activity in animal models via reduction of hepatotoxicity markers (ALT, AST, ALP), restoration of liver antioxidants, and suppression of hepatic oxidative stress. Animal evidence and traditional classification as a liver tonic are consistent; human hepatic endpoint trials are absent.
Hepatoprotective activity of H. spicatum is documented in both in vitro and in vivo preclinical studies. Isolated diterpenes protect hepatocytes from toxin-induced damage, normalizing SGOT/SGPT in CCl4 models. An in vivo feeding study in cockerels showed rhizome powder ameliorated liver damage caused by chronic indoxacarb exposure.
Hesperidin exerts hepatoprotective effects by reducing oxidative stress, inhibiting hepatic stellate cell activation and fibrosis, and protecting against chemical-induced liver injury in preclinical models. It maintains glutathione (GSH) and catalase activity and reduces lipid peroxidation (MDA) in liver tissue. Evidence is primarily preclinical with robust animal data.
Multiple preclinical studies and one human clinical trial demonstrate that Hibiscus sabdariffa extract (HSE) exerts hepatoprotective effects, reducing liver steatosis, liver enzyme elevations, and lipid peroxidation. A 12-week RCT in obese adults found HSE improved liver steatosis. Mechanisms involve downregulation of lipogenic genes and antioxidant upregulation.
L. japonica has documented hepatoprotective effects in preclinical models, including protection against CCl4-induced liver injury, dimethylnitrosamine-induced liver fibrosis, and non-alcoholic steatohepatitis. Extracts reduce ALT, AST, and MDA while increasing GSH, suggesting antioxidative liver protection.
Animal and in vitro studies consistently document hepatoprotective activity of M. vulgare, linked to its antioxidant phenolic compounds and a novel monoterpene acid. WebMD and Drugs.com list liver complaints among traditional uses, while the PMC pharmacological overview includes hepatoprotective activity among the most investigated properties. No human clinical trials exist.
Preclinical studies identify hepatoprotective activity as an established pharmacological property of L. purpureus. Animal models demonstrate protection against induced liver toxicity, and metabolomics studies show attenuation of HFD-induced liver metabolism dysregulation. Hypatroprotective activity is consistently cited in peer-reviewed pharmacology reviews.
In vitro studies have identified hepatoprotective coumarins and secoiridoids in Hydrangea paniculata stems. A PubMed-indexed study (PMID 24811324) isolated new coumarin glucosides and secoiridoid glucosides from H. paniculata stems that showed hepatoprotective activity against DL-galactosamine-induced toxicity in human liver HL-7702 cells at 10 µM. Evidence is limited to cell culture; no animal or human studies confirm liver-specific detoxification effects.
Multiple animal studies demonstrate that Aegle marmelos leaf and fruit extracts protect the liver from chemically-induced damage (CCl4, alcohol, H. pylori toxins), restoring liver enzyme levels (ALT, AST, ALP, bilirubin) and antioxidant enzyme activity. The hepatoprotective activity is attributed to rutin, flavonoids, and coumarins in the extract.
Hepatoprotective activity of H. indicus is one of its most robustly documented pharmacological properties, supported by multiple published animal studies using paracetamol and CCl4 liver injury models. The root extract significantly reduced liver enzyme markers of hepatotoxicity and was comparable to silymarin as a standard reference.
T. cordifolia has well-established hepatoprotective activity in preclinical models (CCl4, lead, anti-tuberculosis drugs) and limited but positive clinical data. Its hepatoprotective effects are mediated through inhibition of lipid peroxidation, antioxidant enzyme induction, and alkaloid-driven anti-inflammatory pathways. A 2024 narrative review in the Journal of Pharmacy and Pharmacology concludes that T. cordifolia 'is an effective hepatoprotective agent against various hepatotoxic substances.'
Animal studies from Annamalai University and others demonstrate hepatoprotective activity of I. tinctoria leaf extracts against chemically induced liver injury, with significant restoration of liver enzymes (AST, ALT, ALP) and antioxidant parameters. This use is also well-rooted in traditional Ayurvedic and TCM practice.
Indole-3-carbinol (I3C) from cruciferous vegetables induces hepatic phase I (CYP1A2) and phase II (GST, UGT) detoxification enzymes, promoting favorable metabolism and excretion of estrogens, carcinogens, and xenobiotics. It is well-documented in the literature on dietary support of hepatic detoxification biotransformation pathways. I3C and its dimer DIM are among the best-studied cruciferous phytochemicals for liver detox enzyme induction.
Inositol plays a role in hepatic lipid metabolism and has been studied in non-alcoholic fatty liver disease (NAFLD). A 2020 systematic review identified RCT evidence for pinitol (a methylated inositol) reducing liver fat, AST levels, and lipid peroxidation. A 2023 RCT of myo-inositol 4 g/day in obese NAFLD patients showed improvements in liver enzymes and cardiometabolic markers versus placebo.
Jiaogulan gypenosides protect liver cells from oxidative stress, lipid accumulation, and inflammatory injury. Animal studies and in vitro work document hepatoprotective mechanisms; a 6-month human clinical study reported positive results as an add-on treatment for non-alcoholic fatty liver disease (NAFLD).
Multiple preclinical studies demonstrate jujube extract protects hepatocytes against alcohol-, acetaminophen-, and CCl4-induced damage by activating the Nrf2 antioxidant pathway and reducing liver enzyme markers (ALT, AST, ALP). Jujube is documented in TCM as a liver tonic. Human clinical evidence is limited to indirect data (liver enzymes in T2D RCTs).
Sulforaphane from kale potently activates Nrf2 in the liver, upregulating phase II detoxification enzymes (GST, NQO1, HO-1) and reducing oxidative stress and lipid peroxidation. I3C from kale's glucobrassicin protects against liver fibrosis and injury in animal models. Traditional medicine also recognizes kale for hepatic health.
Kudzu flower and root have a long TCM history for supporting liver function, particularly in the context of alcohol detoxification. Puerarin isoflavones have demonstrated hepatoprotective effects in animal models by reducing alcohol-induced liver injury through antioxidant mechanisms and modulation of TNF-α and endotoxin receptors. Human evidence is limited to the alcohol-related context.
L-carnitine supports hepatic fatty acid β-oxidation, reduces steatosis in NAFLD, and lowers ammonia in hepatic encephalopathy. Multiple RCTs by Malaguarnera et al. confirmed L-carnitine significantly improved hepatic encephalopathy parameters in cirrhotic patients. A PMC review lists L-carnitine's therapeutic role across NASH, cirrhosis, and hepatocellular carcinoma.
L-cysteine is the rate-limiting amino acid for hepatic glutathione synthesis. GSH is essential for Phase II liver detoxification (conjugation of toxins, drugs, and metabolites for excretion). NAC is the medically established antidote for acetaminophen hepatotoxicity by restoring depleted liver glutathione. Evidence in NAFLD for NAC reducing liver enzyme levels and inflammation is supported by preclinical and limited clinical data.
L-cystine and its reduced form cysteine are precursors for hepatic glutathione, which is central to the liver's phase II detoxification processes. The majority of plasma GSH originates in the liver, and impaired hepatic GSH synthesis has systemic redox consequences. Clinical evidence is primarily mechanistic or derived from cysteine/NAC studies; direct L-cystine liver-detox RCTs are limited.
Glutathione is the liver's primary endogenous antioxidant and phase II detoxification conjugating agent, directly participating in elimination of toxins, heavy metals, and reactive metabolites. Hepatic glutathione depletion is a central mechanism of liver injury from numerous toxins and drugs. Supplemental glutathione and compounds that raise it (NAC, ALA) are specifically used in liver detox contexts.
Glycine is a direct precursor of glutathione (γ-L-glutamyl-L-cysteinyl-glycine), the liver's principal endogenous detoxification antioxidant. Glycine also participates directly in hepatic phase II conjugation (glycine conjugation), detoxifying bile acids and aromatic compounds. Animal studies show hepatoprotective effects, and small clinical trials suggest benefit in chronic hepatitis and fatty liver disease.
Up to 50% of dietary methionine is metabolized in the liver. L-methionine is a precursor to SAMe and to cysteine, the rate-limiting substrate for glutathione (GSH), the liver's primary phase II detoxification antioxidant. SAMe therapy has been evaluated in 41 human liver-disease studies; it restores hepatic GSH and attenuates injury in alcoholic liver disease. Evidence for supplemental L-methionine specifically in healthy individuals is limited; most human data concern SAMe.
L-ornithine is a central intermediate of the hepatic urea cycle, converting toxic ammonia to urea. As the L-ornithine L-aspartate (LOLA) formulation, it is clinically used to treat hepatic encephalopathy (HE) in cirrhosis, with meta-analyses of multiple RCTs confirming significant reductions in blood ammonia and improvements in mental state. Evidence also includes direct hepatoprotective effects such as reductions in liver enzymes and improvements in MELD scores.
L-Threonine plays a lipotropic role in the liver, helping to regulate fat metabolism and prevent hepatic lipid accumulation. Animal studies demonstrate that threonine deficiency causes fatty liver via impaired lipid transport. Threonine is also catabolized in liver mitochondria to glycine, which participates in Phase II detoxification via glycine conjugation. Evidence is predominantly from animal and biochemical studies, not human clinical trials.
Phosphatidylcholine (PC), the main component of lecithin, is essential for hepatic fat export via VLDL synthesis; PC deficiency leads to hepatic steatosis (fatty liver). A double-blind RCT in TPN patients showed lecithin supplementation significantly raised plasma choline and reduced hepatic steatosis. PC has also been studied for alcoholic liver disease and fibrosis in animal and human research.
LEM contains vanillic acid, syringic acid, and low-molecular-weight lignin fractions that demonstrate hepatoprotective effects in multiple animal models of acute and chronic liver injury. LEM reduces liver fibrosis, decreases AST/ALT levels, and inhibits collagen fibril accumulation in preclinical studies.
Glycyrrhizin (injectable form, Stronger Neo-Minophagen C) has been used clinically in Japan for over 30 years to treat chronic viral hepatitis, reducing liver enzyme levels. Preclinical evidence demonstrates licorice reduces ALT, AST, TNF-α, and oxidative stress markers in alcohol-induced and diabetes-related fatty liver models. NCCIH and LiverTox (NIH) acknowledge the hepatoprotective evidence base.
D-limonene is documented to modulate hepatic Phase I and Phase II detoxification enzymes in animal studies, reducing Phase I activity and upregulating Phase II enzymes (glutathione S-transferase, quinone reductase). It also reduces liver transaminase levels and attenuates inflammatory infiltration and lipid accumulation in alcoholic and non-alcoholic liver disease models.
A 1975 double-blind RCT (Preziosi et al.) in 40 hospitalized men with hepatic dysfunction found that IM total liver extract improved liver function markers — including cholesterol, prothrombin time, and hemoglobin — with 60% of treated patients improved versus placebo. Early research also suggests liver extract combined with flavin adenine dinucleotide (FAD) may enhance interferon response in chronic hepatitis C patients.
Ethanol extracts of L. gracile leaf show hepatoprotective activity against carbon tetrachloride (CCl4)-induced liver damage in mice, reducing markers of liver injury. Flavonoids isolated from the leaf also protect against restraint stress-induced liver injury in mice. Evidence is preclinical (animal studies only).
Lotus seed and seedpod extracts protect the liver from chemically induced injury (CCl4, APAP, cisplatin) and reduce hepatic lipid accumulation in obese diabetic animals. In vitro studies confirm direct hepatocyte protection. No human hepatoprotective trials for lotus seed exist.
Luteolin demonstrates significant hepatoprotective effects across NAFLD, NASH, hepatic fibrosis, and liver enzyme normalization in preclinical models and is a key active component in clinically used liver-protective formulations in traditional Chinese medicine practice. Human combination-product trial data also support improvements in hepatic enzyme profiles.
Lychee pericarp polyphenols—especially epicatechin and procyanidin A2—have demonstrated hepatoprotective effects in preclinical models, decreasing liver injury biomarkers (AST, ALT) and preserving hepatocyte structure in CCl4-intoxicated mice. Flavanol-rich lychee extract also suppresses iNOS and TNF-α in hepatocytes, providing anti-inflammatory liver protection. In vitro data show procyanidin A2 supports liver cell regeneration in wound-healing assays and alcohol-injured cells.
Magnolia officinalis bark extract activates the Nrf2 hepatoprotective pathway in human hepatocytes, upregulating antioxidant and detoxification enzymes. Magnolol prevents acute alcoholic liver damage via PI3K/Nrf2/PPARγ pathway activation. In NAFLD patients, magnolia extract has been shown to reduce hepatic fat content.
Maitake supplementation in animal models inhibits hepatic lipid accumulation and modulates liver cholesterol metabolism genes, supporting hepatic lipid processing. Preclinical evidence demonstrates beta-glucans reduce oxidative stress and prevent fat storage in liver tissue. Traditional East Asian use included maitake as a liver tonic to boost qi and protect the organ.
Hepatoprotective activity is documented for Adhatoda vasica through animal studies showing vasicinone's liver-protective effect. Multiple pharmacological reviews list hepatoprotective activity as confirmed. Traditional use includes jaundice and liver conditions.
A 12-week RCT in overweight/obese adults found that daily mango consumption significantly decreased AST (aspartate transaminase) liver enzyme activity, suggesting a hepatoprotective effect. In vitro and animal data support mangiferin's antioxidant and anti-inflammatory properties reducing liver oxidative stress and hepatic inflammation.
Marjoram extract has demonstrated hepatoprotective activity in rat models of liver injury, significantly reducing elevated liver enzymes (AST, ALT, GGT, ALP) and improving hepatic antioxidant status in high-fat diet-induced hepatosteatosis.
MMSC demonstrates hepatoprotective activity in multiple rodent models of chemically-induced liver injury, normalizing liver enzyme biomarkers (ALT, AST, GGT, LDH) and supporting antioxidant defense. It participates in methionine and glutathione metabolism via the BHMT2 enzyme pathway. All robust evidence is preclinical; human clinical liver studies have not been conducted.
Milk thistle (Silybum marianum) and its active extract silymarin have centuries of traditional use for hepatic disorders. Clinical trials show silymarin modestly reduces liver enzyme markers (ALT, AST) and oxidative stress in alcoholic and non-alcoholic liver disease. A pooled analysis of trials in cirrhosis patients found silymarin associated with a significant reduction in liver-related deaths. Evidence is promising but mixed due to small, heterogeneous trials.
Molybdenum-dependent enzymes — aldehyde oxidase, xanthine oxidase, sulfite oxidase, and mARC — are all expressed in the liver and collectively perform critical phase I detoxification reactions. A 2024 PMC review linked dysregulation of XO and mARC to NAFLD and hepatocellular carcinoma. These roles are mechanistically established in human liver biochemistry.
M. officinalis-derived polysaccharides inhibit neutrophil and macrophage infiltration into the liver, acting as immune regulators to alleviate hepatic injury. M. citrifolia demonstrates hepatoprotective activity against CCl4-induced liver damage in rats, attributed to the antioxidant activity of flavonoid constituents.
Morus extracts demonstrate hepatoprotective activity in preclinical studies and in clinical biomarker data. A 2025 meta-analysis found that mulberry supplementation improved AST levels in human trials. Anthocyanins protect hepatocytes from oxidative damage via MAPK and Nrf2 pathways.
Hepatoprotective activity of A. vulgaris aqueous-methanol extract has been demonstrated in rodent models, with normalization of elevated liver enzymes and protection of hepatocytes against oxidative stress. The plant is listed in TCM for hepatitis and its choleretic (bile-stimulating) action is documented. Preclinical findings only; no human hepatoprotection trials exist.
Mulberry extract has demonstrated hepatoprotective effects in cell-based and animal studies, including protection against oxidative damage and lipid accumulation in liver cells. The 2025 meta-analysis of clinical RCTs found mulberry improved AST levels. Mulberry leaf flavonoids protect HepG2 liver cells from Hâ‚‚Oâ‚‚-induced injury via Nrf2 activation.
Mustard seed myrosinase enzyme enhances production of sulforaphane from glucoraphanin in cruciferous foods; sulforaphane is a potent Nrf2 inducer that upregulates hepatic phase II detoxification enzymes. Human RCT evidence confirms that adding mustard seed powder to cooked broccoli significantly increases sulforaphane bioavailability, supporting liver detoxification pathways.
TC water extract pretreatment significantly attenuated drug-induced acute liver injury in mice, reducing serum AST, ALT, and LDH, suppressing hepatic inflammatory cytokines, and restoring antioxidant enzyme activity. TC also prevented liver toxicity from rifampicin/isoniazid combination in animal models.
NAC is the precursor to hepatic glutathione, the liver's primary endogenous antioxidant and detoxification agent. It is FDA-approved (IV form) as the standard-of-care antidote for acetaminophen overdose-induced liver failure. Research also demonstrates benefits in drug-induced liver injury and NAFLD, with clinical trials showing reductions in ALT and improvements in serum albumin and bilirubin.
Naringin protects against liver injury from high-fat diet, chemical toxins, and NAFLD/NASH by reducing hepatic lipid accumulation, restoring antioxidant enzyme activity, and modulating gut microbiota. A 2025 multi-omics study confirmed naringin restores hepatic lipid homeostasis and reshapes gut microbiota in diet-induced liver disease. Evidence is preclinical; no human hepatoprotection RCTs exist.
Human clinical evidence suggests NR with other metabolic cofactors may improve liver health in NAFLD. Post-hoc analysis of a 12-week RCT in obese men showed a suggestion of improved fatty liver in the NR-treated group. Preclinical studies consistently show NR reduces hepatic steatosis, fibrosis, oxidative stress, and lipid accumulation in diet-induced NAFLD models by activating hepatic sirtuin pathways and restoring NAD+ pools.
Animal studies show nopal consumption significantly attenuates hepatic steatosis and oxidative stress in obese rats, reducing hepatic triglycerides by approximately 50% and decreasing liver injury biomarkers (ALT, AST). Nopal modulates hepatic lipid metabolism genes and improves liver insulin signaling. A 2023 PMC review of Opuntia's effects on liver health confirmed positive preclinical evidence across multiple Opuntia species. Human evidence for hepatoprotective effects is limited but mechanistically grounded.
Hepatoprotective activity of C. rotundus is well-documented in preclinical studies. Ethyl acetate extract of rhizomes at 100 mg/kg significantly lowered serum liver enzymes (GOT, GPT, alkaline phosphatase, bilirubin) and protected hepatocytes in carbon tetrachloride-induced liver damage in rats.
Okra pods and roots exhibit hepatoprotective effects via antioxidant activity and boosting enzymatic antioxidant defense systems in multiple animal models. A 2022 PubMed-indexed study showed okra pectic polysaccharide ameliorated CCl4-induced acute liver injury in mice. A 2024 RCT in pre-diabetic adults found okra improved liver transaminase levels.
OA has well-established hepatoprotective effects demonstrated in multiple animal models and acknowledged in Chinese pharmacopeia, where it is listed as a liver-protective drug. It reduces liver enzyme elevations, enhances antioxidant enzyme systems (SOD, GPx), and suppresses inflammation via PPARα and NF-κB pathways. Limited human data suggest potential benefit in hepatitis and liver fibrosis.
Omega-3 fatty acids have documented clinical effects on non-alcoholic fatty liver disease (NAFLD), reducing hepatic fat accumulation, liver enzymes (ALT, AST), and TG levels. A meta-analysis of 7 RCTs found omega-3 supplementation is a practical and effective treatment for NAFLD. Evidence is clearest for early-stage NAFLD, with less benefit in advanced NASH.
Onion and its constituents—especially quercetin—demonstrate hepatoprotective effects by reducing oxidative stress, inflammation, and liver enzyme levels. Human trial data show reductions in AST with onion supplementation. Preclinical studies demonstrate protection against chemical- and toxin-induced liver damage through antioxidant and anti-inflammatory mechanisms.
Oregon grape root is classified as a cholagogue and hepatic stimulant in herbal practice, promoting bile flow through the liver and gallbladder. Berberine shows hepatoprotective effects in multiple animal studies and in RCTs for NAFLD, with significant reductions in ALT, AST, and GGT. Traditional use across Native American, TCM, and Western herbal medicine specifically targets liver stagnation.
Bile acids are synthesized in the liver and are the primary vehicle for hepatic excretion of cholesterol, endogenous metabolites, and xenobiotics into the intestinal lumen. Adequate bile flow is therefore integral to the liver's detoxification function. Exogenous bile acids from ox bile supplements act downstream of the liver in the intestinal lumen and do not directly enhance hepatic synthesis or bile flow; they do not substitute for prescription bile acid therapy in hepatic disease.
P. foetida has demonstrated hepatoprotective activity in multiple preclinical models, protecting against CCl4- and paracetamol-induced liver damage. It significantly normalizes liver enzymes (ALT, AST, ALP) and activates the Nrf2/HO-1 antioxidant pathway in liver tissue. Traditional use in Chinese and Ayurvedic medicine for liver disorders is well-documented.
POA reduces hepatic lipid accumulation (steatosis) in preclinical NAFLD models and suppresses liver inflammatory signaling. It also modulates gut-liver axis dysbiosis, reducing hepatotoxic TMAO formation. Human-specific liver detoxification evidence is limited but plausible given the established lipokine mechanisms.
Pantethine significantly increases hepatic CoA content, which is the rate-limiting cofactor for mitochondrial fatty acid beta-oxidation in the liver. Animal studies and limited human biopsy data indicate pantethine reduces hepatic steatosis and lipid peroxidation. It is postulated to regulate liver sterol biosynthesis and reduce fat accumulation in hepatocytes.
Parsley exhibits hepatoprotective activity across multiple animal models: it reduces liver oxidative stress, normalises liver enzymes (ALT, AST, ALP), and protects hepatic tissue from toxic and diabetic insult. Myristicin induces hepatic glutathione S-transferase, a key phase II detoxification enzyme. Animal evidence is consistent; human data are limited.
Peach kernel extracts have been studied for inhibiting liver fibrosis and hepatic stellate cell activation in vitro, reflecting a long TCM use of peach kernel in liver conditions. Polyphenol-rich peach by-products also reduced hepatic steatosis in obese animals. Evidence is preclinical.
Pear pomace water extract (PPWE) demonstrated hepatoprotective effects in rats fed a high-fat/cholesterol diet, reducing hepatic lipid peroxidation and improving liver enzyme markers (ALT, AST). Pear also stimulates alcohol-metabolizing enzymes (alcohol dehydrogenase, aldehyde dehydrogenase), reducing blood alcohol and acetaldehyde burden — a traditional claim scientifically confirmed.
Berberine from P. amurense protects the liver from chemical-induced hepatotoxicity, stimulates bile secretion and bilirubin discharge, and inhibits hepatic gluconeogenesis. TCM explicitly uses P. amurense for liver heat, jaundice, and hepatitis. Studies on berberine's preventive and curative effects on chemical-induced hepatotoxicity in rodents are cited in the literature (Fitoterapia 2000).
Phosphatidylcholine (PC) is an essential phospholipid critical to hepatocyte membrane integrity and lipid export from the liver. Polyenylphosphatidylcholine has been studied in alcoholic liver disease in a large VA multicenter RCT. A 2024 clinical trials review confirmed phospholipids reduce liver enzymes in clinical studies. Choline deficiency is established as a direct cause of hepatic steatosis.
Picrorhiza kurroa (Kutki) is a Himalayan herb with extensive use in Ayurvedic medicine for liver diseases, jaundice, and hepatitis. Its active constituent kutkin (picrosides I and II) demonstrates hepatoprotective effects including activation of FXR to regulate bile acid balance, antioxidant activity, and anti-cholestatic properties. Both traditional clinical use and preclinical evidence support liver detox applications.
An aqueous extract of P. integerrima was found to have hepatocurative properties in CCl4-induced hepatic injury in rats (Khan et al., 2004). A combination of P. integerrima with Berberis lycium and Galium aparine demonstrated hepatoprotective effects in CCl4-treated rats. Traditional Ayurvedic use for 'yakrit roga' (liver disorders) is well established.
Platycodon root has documented hepatoprotective effects across multiple animal models, including protection against endotoxin-induced acute liver injury, high-fat-diet-induced NAFLD, and chemically induced liver fibrosis. Key markers including ALT, AST, and hepatic lipid accumulation are improved by PG fractions.
Platycodon root extracts and platycodin D exhibit hepatoprotective effects in multiple animal models of liver injury, including alcohol-induced, endotoxin-induced, chemotherapy-induced, and diabetic liver damage. Mechanisms include suppression of ALT/AST elevations, reduction of oxidative stress markers, and inhibition of NF-κB-driven hepatic inflammation.
PUPS (Polyporus umbellatus polysaccharide) is a Chinese SFDA-approved drug for hepatitis B and liver cancer adjunct therapy. It accelerates liver cell repair, reduces serum transaminases, inhibits HBV antigen expression, and protects against chemically induced hepatic damage.
Pomelo coumarins isolated from the peel show hepatoprotective activity in human hepatic cell lines (LO2 cells) by suppressing ALT/AST and boosting antioxidant enzyme activity. Pomelo peel powder prevents hepatic inflammation and fibrosis in CCl4-treated rats. A 2026 Nature npj Science of Food study confirmed pomelo peel extract equivalently alleviates hepatic steatosis, oxidative stress, and inflammation in a diet-induced model.
Animal studies demonstrate hepatoprotective effects of Opuntia extracts via antioxidant-mediated reduction of oxidative stress and lipid peroxidation in liver tissue. Cell studies in human hepatocytes show triglyceride reduction and ALT/AST suppression. Traditional use for liver support and hangover is extensive.
Prunus domestica extracts exhibit hepatoprotective activity in preclinical models. A fiber-containing extract ('Prunophyte') at 200 mg/kg showed laxative and hepatoprotective effects in a rat model of alcoholic liver disease. A 2025 in-vitro study used P. domestica subsp. syriaca extract on steatotic human hepatocytes (MASLD model) and showed beneficial effects on oxidative stress, lipid accumulation, and glucose uptake pathways.
P. marsupium demonstrates hepatoprotective activity in multiple preclinical models. Stem bark and leaf extracts normalize liver enzymes and improve hepatic histology in CCl4- and paracetamol-induced liver injury models in rats.
Multiple preclinical studies have demonstrated hepatoprotective activity of B. diffusa extracts against toxic liver injury, showing reductions in serum ALT, AST, ALP, and bilirubin, and histopathological protection comparable to silymarin at some doses. It is traditionally used in Ayurveda for jaundice, hepatitis, and liver cirrhosis. Evidence comes from animal models; robust human trials are lacking.
A 2021 double-blind RCT in NAFLD patients found purslane extract (12 weeks) significantly reduced liver enzyme markers ALT, AST, and GGT from baseline. A 2024 RCT (n=70, 700 mg/day) found purslane improved lipid profiles and antioxidant enzymes in NAFLD patients, with mixed effects on hepatic steatosis. In vitro studies confirm hepatoprotective activity against toxic injury.
Quercetin modulates hepatic detoxification pathways by activating the Nrf2 transcription factor and upregulating phase I, II, and III xenobiotic-metabolizing enzymes. In animal studies, oral quercetin after CCl4 intoxication significantly reduced ALT/AST liver injury markers and restored antioxidant enzyme expression. Quercetin and its metabolite isorhamnetin have been shown in human cell line studies to reduce benzo[a]pyrene-induced cytotoxicity and BPDE-DNA adduct formation by modulating AhR and NRF2 pathways.
Multiple animal studies and one open-label human pilot study support radish's hepatoprotective and liver detoxification effects. Radish extracts reduce liver enzymes (ALT, AST), stimulate phase I and II detoxification enzymes, and activate the Nrf2/HO-1 antioxidant pathway. The human study used a Spanish black radish supplement and measured accelerated acetaminophen metabolism.
Rehmannia demonstrates hepatoprotective effects across multiple preclinical models, attenuating NAFLD, hepatic steatosis, and drug-induced hepatotoxicity. Catalpol activates AMPK/TFEB autophagy to reduce lipid accumulation; ajugol enhances lysosome-mediated lipophagy; and catalpol modulates CAR/Nrf2 pathways to protect against hepatotoxins. The herb is traditionally used in TCM to 'enter the liver channel' and nourish liver yin.
Rehmannia polysaccharides and oligosaccharides demonstrate hepatoprotective effects in animal models of chemical liver injury. Raffinose family oligosaccharides from RG significantly reduced CCl4-induced liver enzyme elevations (ALT, AST) and increased hepatic antioxidant enzymes. Anti-inflammatory effects on LPS-induced acute liver injury are also documented.
Reishi has documented hepatoprotective effects in preclinical models, confirmed by MSKCC. Antioxidative, anti-inflammatory, and NF-κB suppressive effects in liver tissue are well characterised. In TCM, reishi was used to support liver Qi and detoxification. Human evidence for liver 'detox' per se is lacking; rare cases of hepatotoxicity with poor-quality preparations have been documented.
Multiple human RCTs have evaluated resveratrol for non-alcoholic fatty liver disease (NAFLD), with a comprehensive review identifying its potential for reducing liver fat accumulation and modulating liver enzyme levels. A meta-analysis of placebo-controlled trials found resveratrol had negligible overall effects on NAFLD markers in clinical studies, though preclinical evidence of hepatoprotection is robust. Results in humans are inconsistent across trials.
Rhubarb root is a documented hepatoprotective agent in TCM and preclinical research, used for jaundice, liver inflammation, and fibrosis. Clinical evidence includes its use in chronic hepatic disease treatment and its anti-inflammatory, antifibrotic effects on liver tissue.
Multiple human cohort and mechanistic studies document that coffee consumption is inversely associated with liver enzyme levels (ALT, GGT) and chronic liver disease incidence. Both caffeine and chlorogenic acids—the dominant bioactives in robusta—contribute to hepatoprotective effects. In an animal model comparing arabica and robusta, both coffee species reduced liver triglyceride content and modulated hepatic gene expression linked to glucose and fat metabolism.
Rosemary (Rosmarinus officinalis) and its active diterpenes carnosic acid and carnosol, along with rosmarinic acid, demonstrate hepatoprotective effects in preclinical studies through Nrf2 activation, antioxidant enzyme induction, and NF-κB inhibition. Animal studies show protection against CCl4 and APAP-induced liver injury. Traditional use as a liver tonic and cholagogue is documented in European herbal medicine.
Rosmarinic acid has well-documented hepatoprotective effects in preclinical models, reducing liver damage from chemical toxins (CCl4, LPS/D-galactosamine), cholestasis, and NAFLD via Nrf2 pathway activation, NF-κB suppression, and antioxidant enzyme induction. A comprehensive review (PMID 30780110) characterizes RA's hepatoprotective mechanisms as among its most robustly documented pharmacological properties.
Rubiadin, a major phytochemical constituent of R. cordifolia, demonstrated hepatoprotective effects comparable to silymarin in a CCl4-induced liver injury rat model, significantly reducing malondialdehyde and preserving glutathione. Additional preclinical studies confirm protection against acetaminophen and CCl4-induced hepatotoxicity. Ayurvedic and Unani traditions also recognize the herb for liver-supportive uses including jaundice.
Rutin is extensively studied for hepatoprotective activity, primarily in preclinical models. It activates Nrf2/HO-1 and NF-κB signaling pathways to protect hepatocytes from oxidative and inflammatory injury. A 2025 review in Basic & Clinical Pharmacology & Toxicology summarized evidence across multiple liver disease contexts.
Saffron and its constituents have demonstrated hepatoprotective effects in human trials, including reductions in liver enzymes (ALT, AST) in patients with NAFLD and T2DM. Traditional Tibetan and Persian medicine has long used saffron for liver conditions. A clinical RCT in NAFLD patients showed reduced inflammatory, oxidative, and liver enzyme markers following saffron supplementation.
SAMe is a key methyl donor and glutathione precursor whose hepatic synthesis is depleted in chronic liver disease. Scientific evidence supports its role in ameliorating cholestasis, reducing liver injury markers, and preventing hepatic steatosis. A 2024 systematic review confirms promising improvements in liver parameters in fatty liver disease and hepatitis, though large high-quality RCTs remain limited.
Smilax glabra extracts have demonstrated hepatoprotective activity in multiple animal studies, attributed to resveratrol, oxyresveratrol, flavonoids, and saponins that reduce oxidative liver damage. A PMC-listed review confirms its hepatoprotective classification. Human trial data remain absent, but the preclinical evidence is mechanistically coherent.
Schisandra is one of the most documented hepatoprotective herbs in TCM, used for liver conditions since the Eastern Han Dynasty. Active lignans enhance cytochrome P450 activity, glutathione production, and Nrf2/ARE pathway activation, boosting phase I/II detoxification capacity. Small human trials in hepatitis B/C and NAFLD showed improved liver enzymes. Pharmaceutical derivatives (bifendate, bicyclol) are approved in China for hepatitis.
Schisandrins are the primary active lignans from Schisandra chinensis, a herb used in TCM for centuries specifically for liver disease. Preclinical studies demonstrate schisandrin enhances liver detoxification enzymes, reduces inflammatory cytokines, and attenuates fibrosis. Small clinical trials in hepatitis patients showed improvement in serum ALT levels.
Poria cocos polysaccharides exhibit hepatoprotective effects in preclinical models of alcoholic liver disease and fatty liver, reducing liver injury markers, lipid accumulation, and oxidative stress via Nrf2 and NF-κB signaling. TCM uses include protecting the liver from damp-heat and toxic insults.
Hepatoprotective activity of Scrophularia root is supported by in vitro studies showing protection of hepatocytes against toxic injury. Multiple pharmacological reviews list hepatoprotective activity as a confirmed biological activity of S. ningpoensis root. TCM also classifies the root as having detoxifying properties relating to the liver.
SDG reduces hepatic lipid accumulation, normalizes liver enzymes (ALT, AST), prevents lipid peroxidation, and activates Nrf2-mediated antioxidant detoxification pathways in the liver. Studies in high-fat/high-fructose diet mice showed SDG normalized hepatic triglycerides, cholesterol, and lipid metabolic gene expression after 12 weeks. SDG also mitigates chemically induced liver toxicity via anti-apoptotic and anti-oxidative mechanisms.
Selenium is an essential trace mineral required for synthesis of glutathione peroxidase and thioredoxin reductase—key antioxidant enzymes protecting hepatocytes from oxidative damage. Selenium deficiency impairs liver detoxification capacity and is associated with worse outcomes in liver disease. Clinical studies show selenium supplementation reduces oxidative stress markers and liver enzymes in hepatitis patients.
Sesame lignans — particularly sesamin and sesamol — have documented hepatoprotective effects in preclinical models, including protection against carbon tetrachloride-induced liver injury and modulation of liver enzymes. Sesamin has been shown in animal studies to restore liver enzyme function and detoxification capacity. Human evidence is indirect (via improved liver enzymes in clinical trials) and largely supported by preclinical data.
Lentinan inhibits hepatic fat accumulation and protects liver cells from toxic damage. Vitamin D-enriched shiitake extracts demonstrated significant hepatoprotective effects in immune-mediated hepatitis mouse models, reducing ALT/AST and improving liver histology. Traditional Chinese medicine has long used shiitake to support liver function and nourish the blood.
Z. bungeanum extracts have demonstrated hepatoprotective effects in rodent liver toxicity models, reducing ALT, AST, and lipid peroxidation. Z. bungeanum amides ameliorated NAFLD in HFD mice via AMPK/Nrf2 activation. Evidence is exclusively preclinical.
A. julibrissin demonstrates hepatoprotective activity in preclinical models, protecting liver cells from toxic injury and modulating liver enzyme activity. TCM also classifies it as a herb that benefits the liver meridian. Formal clinical liver studies are lacking.
Silymarin has the most robust clinical evidence for hepatoprotection. A 2023 systematic review of 29 RCTs (3,846 participants) confirmed its antioxidative, anti-inflammatory, and antifibrotic effects on liver enzymes. It is used in Europe as an adjunct for alcoholic liver disease, drug-induced liver injury, NAFLD, and viral hepatitis. Evidence for chronic HCV is mixed, with one large JAMA RCT showing no significant ALT reduction vs. placebo.
Hepatoprotective effects of Smilax extracts have been demonstrated in animal models of liver damage, and a study of S. regelii ethanol extract showed protection against CCl4-induced hepatocellular damage in rats. S. china polysaccharide activated Nrf2-ARE antioxidant pathways protecting against APAP-induced acute liver injury. The genus has a long traditional use across multiple systems for liver disease.
Oxymatrine and matrine from S. flavescens are approved in China for treatment of chronic hepatitis B and have documented hepatoprotective, anti-fibrotic, and antiviral properties. S. flavescens extract reduces liver injury markers (ALT, AST) in alcohol-induced liver disease models and has anti-hepatic fibrosis effects.
A. muricata leaf extracts show hepatoprotective activity in rodent models of chemically induced liver damage, restoring liver function markers toward normal. Bilirubin-lowering and hepatoprotective effects have been demonstrated in multiple pre-clinical studies.
Spinach has documented hepatoprotective activity in animal models, attributed to its antioxidant phytochemicals reducing lipid peroxidation and supporting phase II detoxification enzymes. The 2025 ScienceDirect comprehensive review includes hepatoprotective properties among spinach's evidence-based biological activities.
Spirulina, a blue-green algae rich in phycocyanin and chlorophyll, demonstrates hepatoprotective effects in preclinical models and emerging clinical trials, reducing liver enzyme markers and oxidative stress. A 2025 PMC review confirmed spirulina's capacity to reduce liver damage biomarkers and facilitate heavy metal elimination from the body. A 2024 comprehensive clinical trials review confirmed spirulina reduced liver enzymes in clinical studies.
Stigmasterol ameliorates hepatic steatosis, reduces fat accumulation, and modulates bile acid metabolism and lipogenic gene expression in high-fat diet animal models. It also reduced liver enzyme markers (ALT, AST) in toxicity models, supporting hepatoprotective activity.
Sulforaphane, an isothiocyanate from cruciferous vegetables (especially broccoli sprouts), is one of the most potent known activators of Nrf2, upregulating a battery of phase II hepatic detoxification and antioxidant enzymes. Clinical studies show sulforaphane reduces AFB1-DNA adducts and liver cancer biomarkers. It is a key compound in the literature on dietary support of hepatic detoxification.
Sulforaphane glucosinolate (glucoraphanin) is the direct precursor to sulforaphane in broccoli and other cruciferous vegetables, converted by myrosinase to sulforaphane upon ingestion. It supports liver detoxification by generating sulforaphane, the most potent dietary activator of hepatic Nrf2-mediated phase II detoxification enzyme upregulation. It is specifically listed in CaringSunshine's hepatic detoxification database as a liver support compound.
Animal studies confirm hepatoprotective activity of A. calamus extract, including amelioration of alcohol-induced hepatotoxicity and normalization of liver enzyme markers. A 2021 PMC mouse study demonstrated hepatoprotective and nephroprotective activity with histopathological and biochemical confirmation.
Hepatoprotective activity is among the most rigorously studied properties of Swertia chirayita. Multiple preclinical studies demonstrate protection against CCl4-, paracetamol-, and D-galactosamine-induced liver injury via antioxidant and anti-inflammatory mechanisms. The genus has centuries of documented use in treating jaundice and hepatitis across Asian traditional medicine systems.
Taurine is a principal hepatoprotective amino acid, conjugating bile acids, detoxifying hypochlorous acid into taurine-chloramine, and protecting hepatocytes from cytochrome P450 2E1-mediated oxidation. Clinical meta-analyses confirm taurine supplementation significantly reduces liver enzymes AST and ALT.
Teasel root has documented TCM use as a liver tonic and is also used in European herbalism to 'clear liver obstructions and treat jaundice.' Preclinical pharmacological reviews confirm hepatoprotective activity among the established bioactivities of Dipsacus asper. No human clinical trials have evaluated liver detoxification endpoints.
T. chebula has documented hepatoprotective activity supported by animal studies and traditional pharmacopoeia use. It reduces serum liver enzymes (AST, ALT, LDH) and attenuates hepatic oxidative stress and inflammatory cytokines in experimental liver injury models. Traditionally, T. chebula is listed in the Ayurvedic Pharmacopoeia as a liver tonic and included in Triphala for liver and kidney support.
T. cordifolia exerts hepatoprotective effects against chemical-induced liver damage (CCl4, paracetamol, ethanol), normalizing liver enzymes (SGOT, SGPT, ALT, AST, bilirubin) in experimental models. It also showed hepatoprotective and anti-stress activity in a study on chronic alcoholics. Preclinical evidence for liver protection is extensive.
Trimethylglycine (betaine) is a methyl donor used in liver detoxification pathways, particularly the betaine-homocysteine methyltransferase (BHMT) reaction that remethylates homocysteine to methionine, feeding into SAMe synthesis. Clinical trials demonstrate betaine anhydrous reduces hepatic fat, ALT, AST, and histological injury in NAFLD and alcoholic liver disease patients.
Multiple RCTs demonstrate tocotrienols reduce liver enzymes (ALT, AST), hepatic steatosis, and inflammation in NAFLD patients. A 1-year placebo-controlled RCT in 87 hypercholesterolemic adults with NAFLD showed significantly higher hepatic normalization rates in the tocotrienol group. A 24-week RCT with δ-tocotrienol confirmed improved hepatocellular injury biomarkers.
Pterostilbene reduces hepatic oxidative stress, attenuates NAFLD progression, and modulates lipid metabolism genes in multiple animal studies. A human combination trial (NR + pterostilbene) in NAFLD patients showed reduced markers of hepatic inflammation. PTE activates Nrf2, AMPK/mTOR, and SIRT1 pathways in liver cells.
Triphala, the Ayurvedic polyherbal formulation of Terminalia chebula, Terminalia bellirica, and Phyllanthus emblica, has centuries of traditional use for hepatitis, gastritis, and liver support in Indian and Chinese medicine. Preclinical studies demonstrate hepatoprotective effects against CCl4-induced acute liver injury via Nrf2 activation and antioxidant mechanisms. Traditional clinical use for liver conditions is well-documented.
Turmeric's active constituent curcumin has been used in Ayurvedic medicine for liver diseases for centuries. Scientific evidence shows curcumin modulates NF-κB, TGF-β/Smad, and Nrf2 pathways relevant to hepatic inflammation, steatosis, and fibrosis. A meta-analysis of RCTs found curcumin significantly reduced AST and ALT in MAFLD patients. NIH LiverTox notes active evaluation for liver diseases, though rigorous clinical proof is still evolving.
Multiple preclinical studies demonstrate vanillin and vanillic acid protect the liver against chemically induced hepatotoxicity. Vanillin pretreatment in CCl4-treated rats significantly normalized liver enzymes (ALT, AST), inhibited lipid peroxidation, restored antioxidant enzymes (SOD, catalase, GSH), and prevented hepatic necrosis. All evidence is animal-based.
Vitamin E is one of the few supplements with robust RCT evidence in non-alcoholic steatohepatitis (NASH), a form of liver disease driven by oxidative stress. The landmark PIVENS trial (n=247 adults, 800 IU/day for 96 weeks) showed significantly improved liver histology versus placebo. NIH's LiverTox database confirms these findings.
Wasabi isothiocyanates are potent inducers of hepatic Phase II detoxification enzymes—including glutathione S-transferase and HO-1—via Nrf2/Keap1-ARE pathway activation, a mechanism well-established in liver cell models. Wasabi's long-chain ITCs are reported to be substantially more potent than standard isothiocyanates (such as those in broccoli) at inducing Phase II enzymes. Animal data also show wasabi protects against liver fat deposition in metabolic syndrome models.
Watercress's primary bioactive PEITC modulates hepatic phase I and phase II detoxification enzymes, a mechanism studied in animals and indirectly in humans through urinary metabolite analysis. The liver is the primary site of PEITC's detoxification activity, and PMC research confirms PEITC derived from dietary watercress achieves plasma concentrations sufficient to induce detox-related gene expression changes.
Yarrow demonstrates hepatoprotective activity in animal models, reducing liver enzyme elevations and toxic liver injury. Its choleretic action (Commission E approved) supports hepatic clearance. The 2020 PMC study showed improvements in liver enzymes in diabetic rats treated with yarrow extract.
Berberine, the active constituent of Yellow Root, has well-documented hepatoprotective effects studied in multiple clinical trials and meta-analyses, improving liver enzyme levels, lipid metabolism, and bile acid regulation. A 2024 meta-analysis of RCTs confirmed berberine's efficacy in improving liver enzymes and lipid profiles in NAFLD patients. Yellow Root was also traditionally used for jaundice.
In vitro cell studies show zeolite clinoptilolite suppresses NF-κB, TNF-alpha, and IL-1B in liver cells and reverses adriamycin-induced liver damage. Animal studies show reduced heavy metal accumulation in the liver. Human clinical evidence for direct liver detoxification is indirect—reduced circulating heavy metals and contaminants that would otherwise accumulate in the liver. Robust clinical liver endpoint data in humans are absent.
Zinc is an essential mineral required for hepatic alcohol metabolism enzymes (alcohol dehydrogenase, aldehyde dehydrogenase), phase II detoxification enzyme metallothionein induction, and liver regeneration. Zinc deficiency is common in alcoholic liver disease and cirrhosis. Clinical studies demonstrate zinc supplementation improves liver enzyme levels, reduces oxidative stress, and supports liver regeneration in chronic liver disease patients.
Alfalfa is traditionally described as a liver tonic and detoxifying agent in herbal medicine, with chlorophyll credited as the active constituent. Animal studies show alfalfa extract reduces liver enzyme elevations and histopathological liver damage. No human clinical trials support hepatoprotective use.
Apricot and related Prunus species (especially Japanese apricot, Prunus mume) have documented hepatoprotective properties in pharmacological reviews, including effects studied in liver disease patients. The Prunus armeniaca review (PMC9325146) lists hepatoprotective activity among the confirmed pharmacological effects. Traditional medicine uses apricot for liver support. Most human evidence relates to MK615, a Prunus mume extract.
Asparagus root infusions have been used in traditional European and Asian medicine for liver complaints including jaundice and congestive torpor of the liver, and the plant appears in pharmacopoeias listing hepatic indications. Animal studies show hepatoprotective effects against oxidative liver damage induced by high-cholesterol diets. No human RCT evidence for liver detoxification has been established.
Barberry (Berberis vulgaris) is a traditional European, Middle Eastern, and Ayurvedic herb used for liver conditions, jaundice, and bile stimulation, with berberine as its primary hepatoprotective constituent. Its traditional use as a cholagogue and liver tonic is documented across multiple medical traditions. Hepatoprotective activity is scientifically attributed to its berberine content.
Birch buds have been used as cholagogues (bile-stimulating agents) particularly in Eastern European and Russian herbal traditions. Birch bark constituents including betulin have been studied for hepatoprotective activity in preclinical models. A small pilot study explored birch bark extract in chronic hepatitis C patients. Traditional use for liver support is documented.
Animal studies suggest walnut extracts may protect the liver from oxidative stress and reduce liver fat accumulation. Traditional herbal practice classifies black walnut as a liver tonic and detoxifying agent. Human evidence for direct liver detoxification is absent.
Blessed thistle has a long traditional use as a hepatic tonic and liver stimulant, with documented use for jaundice, liver sluggishness, and liver complaints. The bitter constituents are thought to stimulate bile production and liver activity. Animal data suggest some hepatoprotective effects, but no human clinical trials confirm liver detoxification benefits.
Buckthorn has a documented traditional use as a depurative — an herb believed to purify the blood and support liver function by expelling waste and toxins from the body. Traditional Chinese Medicine (TCM) also categorizes buckthorn as 'clearing toxins' and supporting liver function. These claims are not supported by clinical trial evidence.
Bupleurum (Chai Hu) is one of the most important traditional Chinese medicine herbs for liver health, used for over 2000 years in formulas like Xiao Chai Hu Tang (Minor Bupleurum Combination) for liver Qi stagnation, hepatitis, and jaundice. Its active saikosaponins demonstrate anti-inflammatory and hepatoprotective effects in preclinical models. Clinical use in TCM for liver conditions is extensively documented.
Bupleurum falcatum (Sickle-leaf hare's ear, Chai Hu) is the primary species used in TCM for liver Qi stagnation, hepatitis, and jaundice, with active saikosaponins demonstrating preclinical hepatoprotective effects. It is listed in authoritative hepatic ingredient databases as liver-support relevant. Traditional use for liver health in East Asian medicine is extensively documented.
Cleavers has traditional use for jaundice and liver support across European and Balkan herbalism, classified as a hepatic and depurative herb. A rodent study published in 2022 found significant hepatoprotective effects against APAP-induced liver damage. Human evidence is absent.
Corn silk has traditional use in Chinese medicine for liver conditions including jaundice and fatty liver, with documented hepatoprotective activity. Preclinical studies show corn silk extract reduces hepatic lipid accumulation and protects against toxic liver injury. Human clinical evidence is sparse.
Goldenseal (Hydrastis canadensis) is a traditional Native American and Eclectic medicine herb for liver and digestive conditions, containing berberine as its primary hepatoprotective constituent. Traditional use for liver conditions, jaundice, and bile stimulation is well-documented. Its hepatoprotective activity derives primarily from its berberine content, which has documented scientific evidence for liver enzyme reduction.
Guggul is described in Ayurveda as a liver stimulant and is used in formulations for liver conditions including liver abscess and hepatic dysfunction. Preclinical studies suggest guggulipid may have hepatoprotective antioxidant effects, but clinical hepatoprotective trials are absent.
H. antidysenterica is used in Ayurveda and Unani for liver disorders, jaundice, biliousness, and hepatosplenomegaly. A preclinical review characterizes hepatoprotective properties attributable to antioxidant and anti-inflammatory mechanisms. No human hepatology trials have been published.
The juice of fresh I. aquifolium leaves has a documented traditional use for treating jaundice, suggesting a historical association between holly and liver function. The 2022 preclinical study also found reduced liver adiposity with I. aquifolium fractions.
Acacia nilotica is traditionally used in Mali and Sudan for liver diseases. Animal studies confirm hepatoprotective effects of A. nilotica extract against acetaminophen-induced liver damage, with improvements in ALT, AST, and GSH. Gum arabic supplementation in haemodialysis patients significantly reduced liver enzyme markers.
In traditional Chinese medicine, Hu Zhang (P. cuspidatum) is classified as entering the liver and gallbladder meridians and is used to disperse blood stasis, eliminate toxins, and resolve damp-heat in liver disorders. It is listed in the Chinese Pharmacopoeia for removing dampness and reducing jaundice. Resveratrol has shown hepatoprotective activity in preclinical models.
Lemongrass demonstrates hepatoprotective effects in animal studies, protecting against paracetamol- and oxidative stress-induced liver damage. A Springer book chapter confirms hepatoprotective effects of C. citratus in preclinical models. Traditional use for liver and digestive system complaints is documented. No human clinical trials exist.
Traditional Chinese medicine records Syringa use for acute icteric hepatitis, documented in peer-reviewed genus reviews. S. oblata (a related Syringa species) has in vivo and clinical-level data on hepatoprotection. S. vulgaris extract showed hepatoprotective activity in animal experiments. These uses are traditional but supported by preclinical data.
Momordica charantia is used in traditional medicine across Africa and Asia for liver diseases including hepatitis and jaundice. Preclinical evidence demonstrates hepatoprotective and antioxidant activity in liver tissue. Clinical hepatoprotective relevance in humans has not been established in RCTs.
Neem is classified as a 'detoxifying' herb in Ayurveda and Unani medicine, traditionally used to purify blood and support liver function. Preclinical studies show neem extracts protect liver cells from CCl4- and paracetamol-induced damage, with nimbolide showing hepatoprotective effects comparable to silymarin in animal models. Human clinical evidence for liver protection specifically is absent.
Pennycress is classified as a hepatic (liver-supporting) herb in both European and Chinese traditional medicine and was traditionally used to increase bile secretion and 'cleanse toxins.' The plant has been described as a depurative and blood purifier in multiple traditions. No clinical trials have evaluated hepatoprotective effects specifically.
Red root is classified as hepatoprotective and hepatorestorative in naturopathic herbalist monographs, with documented traditional use for liver conditions including fatty liver and hepatitis. 19th-century herbalists and homeopathic materia medica also list liver complaints as an indication. No controlled human trials on hepatic function have been published.
Rhodiola rosea has documented hepatoprotective properties in pre-clinical models, including reduction of liver lipid peroxidation and transaminase levels and enhancement of hepatic antioxidant enzyme activity. These effects have not been demonstrated in controlled human trials, and 'liver detox' as a specific clinical outcome has not been investigated in humans. The traditional use for liver support is cross-referenced in herbal monographs.
Sheep's sorrel has a documented traditional role as a 'depurative' and liver tonic in folk herbal medicine, used to support liver function and detoxification. Genus-level scientific data suggest hepatoprotective activity. No human clinical data exist for R. acetosella.
Shepherd's purse is documented in Russian and Eastern European folk medicine for liver and gallbladder complaints. Preclinical studies confirm hepatoprotective effects, including a rat study showing protection against chemically induced hepatocarcinoma. Multiple pharmacological reviews classify it as having hepatoprotective pharmacological activity.
S. baicalensis has documented hepatoprotective activity against multiple types of liver injury in preclinical models, including xenobiotic and toxic liver damage. TCM has used Huang Qin for jaundice and liver disease for over 2,000 years. The term 'liver detox' maps to hepatoprotection from toxic injury, where baicalin's mechanisms are well-documented.
Stevia has traditional use in South American herbal medicine for liver support. In vitro and animal studies show stevia extracts exert hepatoprotective effects, reducing liver injury markers (AST, ALT), inhibiting hepatic steatosis, and protecting against chemically induced liver damage. No human clinical trials specifically targeting liver detoxification endpoints have been conducted.
Stillingia was traditionally used for liver congestion and torpid liver conditions in Eclectic medicine, classified as a cholagogue and hepatic stimulant. Historical texts document its use for liver affections alongside lymphatic and skin conditions. No clinical evidence exists.
Wheatgrass has been used as a liver detoxifying agent since the 1930s, popularized by Ann Wigmore and naturopathic traditions. Animal studies show hepatoprotective effects with normalized liver enzymes under toxic exposure. Human clinical evidence for liver detoxification specifically is absent.
Liver disorders are listed among the traditional oral indications for yucca by Drugs.com, Rxlist, and traditional medicine references. Native American and folk medicine traditions described yucca as a body-cleansing and detoxifying plant. No human hepatic function clinical trial for yucca exists.
Go back